---
document_datetime: 2024-12-05 12:47:26
document_pages: 82
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/theralugand-epar-public-assessment-report_en.pdf
document_name: theralugand-epar-public-assessment-report_en.pdf
version: success
processing_time: 37.2279362
conversion_datetime: 2025-12-23 22:18:45.086879
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

19 September 2024 EMA/468008/2024 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Theralugand

International non-proprietary name: lutetium (177Lu) chloride

Procedure No. EMEA/H/C/005882/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                     | 8                                                                                                               |
|------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier                                                                                               | .....................................................................................8                          |
| 1.2. Legal basis and dossier content..............................................................................8          |                                                                                                                 |
| 1.3. Information on Paediatric requirements                                                                                  | ..................................................................8                                             |
| 1.4. Information relating to orphan market exclusivity                                                                       | ....................................................8                                                           |
| 1.4.1. Similarity                                                                                                            | .........................................................................................................8      |
| 1.5. Scientific advice...................................................................................................8   |                                                                                                                 |
| 1.6. Steps taken for the assessment of the product                                                                           | ........................................................8                                                       |
| 2. Scientific discussion..............................................................................                       | 10                                                                                                              |
| 2.1. Problem statement.............................................................................................          | 10                                                                                                              |
| 2.1.1. Disease or condition                                                                                                  | ........................................................................................ 10                     |
| 2.2. About the product ..............................................................................................        | 10                                                                                                              |
| 2.3. Type of Application and aspects on development....................................................                      | 11                                                                                                              |
| 2.4. Quality aspects                                                                                                         | .................................................................................................. 11           |
| 2.4.1. Introduction....................................................................................................      | 11                                                                                                              |
| 2.4.2. Active Substance.............................................................................................         | 12                                                                                                              |
| General information                                                                                                          | .................................................................................................. 12           |
| Manufacture, characterisation and process controls.......................................................                    | 12                                                                                                              |
| Specification                                                                                                                | ............................................................................................................ 13 |
| Stability................................................................................................................... | 13                                                                                                              |
| 2.4.3. Finished Medicinal Product................................................................................            | 13                                                                                                              |
| Description of the product and Pharmaceutical development                                                                    | .......................................... 13                                                                   |
| Manufacture of the product and process controls ..........................................................                   | 14                                                                                                              |
| Product specification                                                                                                        | ................................................................................................. 15            |
| Stability of the product..............................................................................................       | 15                                                                                                              |
| Adventitious agents                                                                                                          | .................................................................................................. 16           |
| 2.4.4. Discussion on chemical, pharmaceutical and biological aspects..............................                           | 16                                                                                                              |
| 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                    | ...................... 16                                                                                       |
| 2.4.6. Recommendations for future quality development ...............................................                        | 16                                                                                                              |
| 2.5. Non-clinical aspects............................................................................................        | 17                                                                                                              |
| 2.5.1. Introduction....................................................................................................      | 17                                                                                                              |
| 2.5.2. Pharmacology.................................................................................................         | 17                                                                                                              |
| 2.5.3. Pharmacokinetics                                                                                                      | ............................................................................................ 18                 |
| 2.5.4. Toxicology......................................................................................................      | 24                                                                                                              |
| 2.5.5. Ecotoxicity/environmental risk assessment.........................................................                    | 32                                                                                                              |
| 2.5.6. Discussion on non-clinical aspects .....................................................................              | 32                                                                                                              |
| 2.5.7. Conclusion on the non-clinical aspects                                                                                | ............................................................... 35                                              |
| 2.6. Clinical aspects ..................................................................................................     | 35                                                                                                              |
| 2.6.1. Introduction....................................................................................................      | 35                                                                                                              |
| 2.6.2. Clinical pharmacology                                                                                                 | ...................................................................................... 36                       |

<div style=\"page-break-after: always\"></div>

| 2.6.3. Discussion on clinical pharmacology...................................................................            | 40                                                                                                         |
|--------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
| 2.6.4. Conclusions on clinical pharmacology.................................................................             | 41                                                                                                         |
| 2.6.5. Clinical efficacy                                                                                                 | ............................................................................................... 41         |
| 2.6.6. Discussion on clinical efficacy............................................................................       | 59                                                                                                         |
| 2.6.7. Conclusions on the clinical efficacy ....................................................................         | 59                                                                                                         |
| 2.6.8. Clinical safety                                                                                                   | ................................................................................................. 59       |
| 2.6.9. Discussion on clinical safety..............................................................................       | 71                                                                                                         |
| 2.6.10. Conclusions on clinical safety ..........................................................................        | 75                                                                                                         |
| 2.7. Risk Management Plan........................................................................................        | 75                                                                                                         |
| 2.7.1. Safety concerns                                                                                                   | .............................................................................................. 75          |
| 2.7.2. Pharmacovigilance plan....................................................................................        | 75                                                                                                         |
| 2.7.3. Risk minimisation measures..............................................................................          | 76                                                                                                         |
| 2.7.4. Conclusion......................................................................................................  | 78                                                                                                         |
| 2.8. Pharmacovigilance                                                                                                   | ............................................................................................. 78           |
| 2.8.1. Pharmacovigilance system................................................................................          | 78                                                                                                         |
| 2.8.2. Periodic Safety Update Reports submission requirements                                                            | ..................................... 78                                                                   |
| 2.9. Product information............................................................................................     | 78                                                                                                         |
| 2.9.1. User consultation                                                                                                 | ............................................................................................ 78            |
| 2.9.2. Labelling exemptions .......................................................................................      | 78                                                                                                         |
| 3. Benefit-Risk Balance.............................................................................                     | 79                                                                                                         |
| 3.1. Therapeutic Context ...........................................................................................     | 79                                                                                                         |
| 3.1.1. Disease or condition                                                                                              | ........................................................................................ 79                |
| 3.1.2. Available therapies and unmet medical need.......................................................                 | 79                                                                                                         |
| 3.1.3. Main clinical studies.........................................................................................    | 79                                                                                                         |
| 3.2. Favourable effects..............................................................................................    | 79                                                                                                         |
| 3.3. Uncertainties and limitations about favourable effects.............................................                 | 79                                                                                                         |
| 3.4. Unfavourable effects...........................................................................................     | 79                                                                                                         |
| 3.5. Uncertainties and limitations about unfavourable effects                                                            | ......................................... 80                                                               |
| 3.6. Effects Table...................................................................................................... | 80                                                                                                         |
| 3.7. Benefit-risk assessment and discussion.................................................................             | 80                                                                                                         |
| 3.7.1. Importance of favourable and unfavourable effects..............................................                   | 80                                                                                                         |
| 3.7.2. Balance of benefits and risks ............................................................................        | 81                                                                                                         |
| 3.7.3. Additional considerations on the benefit-risk balance ...........................................                 | 81                                                                                                         |
| 3.8. Conclusions                                                                                                         | ....................................................................................................... 81 |
| 4. Recommendations.................................................................................                      | 81                                                                                                         |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

¹¹¹In

indium-111

¹⁷⁷Lu

lutetium-177

¹⁷⁷Lu -DOTATATE

¹⁷⁷Lu -oxodotreotide

¹⁷⁷Lu -PSMA-617

¹⁷⁷Lu -vipivotide tetraxetan

⁹⁰ Y

yttrium-90

²²³Ra

radium-223

ADT

androgen deprivation therapy

AE

adverse event

AKD

acute kidney disease

AKI

acute kidney injury

ALP

alkaline phosphatase

AML

acute myeloid leukaemia

ART

active reference time

AST

aspartate transaminase

BED

biologically effective dose

BM

bone marrow

BMI

body mass index

CI

confidence interval

CgA

chromogranin A

CKD

chronic kidney disease

CR

complete response

CT

computed tomography

CTCAE

common terminology criteria for adverse events

D

day

DCR

disease control rate

DOTA

1,4,7,10-tetraazacyclododecane-N,N',N',N''-tetraacetic acid

DOTATATE

DOTA-D-Phe¹-Tyr³- Thr⁸ -octreotate

ECOG

Eastern Cooperative Oncology Group

EEA

European Economic Area

Egfr

estimated glomerular filtration rate

EMA

European Medicines Agency

EU

European Union

F

female

GBq

gigabecquerel

GEP

gastroenteropancreatic

GFR

glomerular filtration rate

GHS

global health status

GMP

good manufacturing practice

Hb

haemoglobin

HP

haematological parameters

HPLC

high performance liquid chromatography

HR

hazard ratio

ICH

International Council for Harmonisation

IL

interleukin

i.m.

intramuscular

IQR

interquartile range

i.v.

intravenous

LDH

lactate dehydrogenase

M

male

MA

marketing authorisation

mCi

millicurie

mCRPC

metastatic castration-resistant prostate cancer

MDS

myelodysplastic syndrome

MIRD

medical internal radiation dose

MPN

myeloproliferative neoplasm

MR

minimal response

MRI

magnetic resonance imaging

N/A

not applicable

ND

not determined

NEN

neuroendocrine neoplasm

<div style=\"page-break-after: always\"></div>

NET

neuroendocrine tumour

NR

not reached

OLINDA/EXM

organ level internal dose assessment/exponential modeling

OR

odds ratio

ORR

objective response rate

OS

overall survival

PD

progressive disease

PET

positron emission tomography

PFS

progression-free survival

PHD

persistent haematologic dysfunction

Ph. Eur.

European Pharmacopeia

PPI

present pain intensity

PR

partial response

PRRT

peptide receptor radiotherapy

PRLT

PSMA radioligand therapy

PSA

prostate-specific antigen

PSMA

prostate surface membrane antigen

QoL

quality of life

RBC

red blood cells

RECIST

response evaluation criteria in solid tumours

RLT

radioligand therapy

SAE

serious adverse event

SCr

serum creatinine

SD

standard deviation

SmPC

summary of product characteristics

SPECT

single photon emission computed tomography

SST

somatostatin

SSTR

somatostatin receptor

SUV

standardised uptake value

SUVmax

maximum standardised uptake value

SWOG

Southwest Oncology Group

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

| TEAE   | treatment-emergent adverse event   |
|--------|------------------------------------|
| US     | United States of America           |
| vs.    | versus                             |
| WBC    | white blood cells                  |
| WHO    | World Health Organization          |
| wks.   | weeks                              |
| y      | years                              |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Eckert &amp; Ziegler Radiopharma GmbH submitted on 28 July 2023 an application for marketing authorisation to the European Medicines Agency (EMA) for Theralugand, through the centralised procedure under Article 3 (2) (a) of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 25 February 2021.

The applicant applied for the following indication: Theralugand is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium ( 177 Lu) chloride.

## 1.2. Legal basis and dossier content

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application

The application submitted is composed of administrative information, complete quality data, non-clinical and clinical data based on applicants' own tests and/or studies and bibliographic literature substituting/supporting certain test(s) or study(ies).

## 1.3. Information on paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0433/2021 on the granting of a (product-specific) waiver.

## 1.4. Information relating to orphan market exclusivity

## 1.4.1. Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## 1.5. Scientific advice

The applicant did not seek scientific advice from the CHMP.

## 1.6. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Janet Koenig

Co-Rapporteur:  Antonio Gomez-Outes

CHMP Peer reviewer(s): N/A

<div style=\"page-break-after: always\"></div>

| The application was received by the EMA on                                                                                                                                                  | 28 July 2023      |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| The procedure started on                                                                                                                                                                    | 17 August 2023    |
| The CHMP Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                                                                | 17 November 2023  |
| The CHMP Co-Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                                                             | 23 November 2023  |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC and CHMP members on                                                                                                | 21 November 2023  |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                                                                     | 14 December 2023  |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                                                                         | 26 March 2024     |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Questions to all CHMP and PRAC members on                             | 07 May 2024       |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                    | 16 May 2024       |
| The CHMP agreed on a list of outstanding issues in writing to be sent to the applicant on                                                                                                   | 30 May 2024       |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                             | 19 August 2024    |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on                    | 03 September 2024 |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Theralugand on | 19 September 2024 |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Problem statement

The applicant is seeking marketing authorisation for the proposed medicinal product lutetium ( 177 Lu) chloride solution in accordance with Article 8.3 of Directive 2001/83/EC - complete and independent application, based on full but mixed application with the results of a nonclinical dosimetry study and supportive scientific literature.

The applied and recommended indication is as follows: Theralugand is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium ( 177 Lu) chloride (see SmPC section 4.1).

Theralugand is only to be used by specialists experienced with in vitro radiolabelling (see SmPC section 4.2).

The quantity of Theralugand required for radiolabelling and the quantity of lutetium ( 177 Lu)-labelled medicinal product subsequently administered will depend on the medicinal product radiolabelled and its intended use (see SmPC section 4.2).

## 2.1.1. Disease or condition

Theralugand was developed as a radiopharmaceutical precursor to be clinically used for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with  177 LuCl3.

Radionuclides have widely been used in medical applications such as diagnostic radiology for decades, with the first radiopharmaceuticals commercialised in 1950. For example, tumours as well as metastases can be localised by radionuclide-tracer-complexes specifically targeting tumour-tissue, such as prostate-specific membrane-antigen (PSMA) or somatostatin-analogues (Sgouros G, 2020).

In order to illustrate the clinical utility of  177 Lu data, two indications for which recently specific products using the here applied radioligand therapy (RLT) precursor added to specific carrier molecules (octreotide and PSMA) were selected. For both indications specific products were approved in the EU. This is intended to serve as basis for the benefit-risk assessment of  177 Lu-based therapies as recommended in the relevant RLT guideline.

## 2.2. About the product

Theralugand is a sterile solution of lutetium ( 177 Lu) chloride in diluted hydrochloric acid containing 40 GBq/ml of lutetium ( 177 Lu) chloride.

Lutetium belongs to the group of lanthanides, also referred to as rare-earths elements in the historical literature that consists of 15 chemical elements, mainly trivalent, f-electronic, silvery-white metals, such as cerium, praseodymium, europium, dysprosium, ytterbium, neodymium, gadolinium, etc. (Palasz, et al. 2000)

177 Lu is a radioactive lutetium isotope that emits beta-particles upon decay to stable hafnium ( 177 Hf) with a half-life of 6.647 days. The primary radiation emissions of  177 Lu are presented in Table 1 .

Table 1: Lutetium ( 177 Lu) principle radiation emission data

| Radiation   |   Energy (keV)* |   Abundance (%) |
|-------------|-----------------|-----------------|
| Beta ( β- ) |           47.23 |           11.66 |

<div style=\"page-break-after: always\"></div>

| Beta ( β- )   |   111.20 |   8.89 |
|---------------|----------|--------|
| Beta ( β- )   |   148.84 |  79.44 |
| Gamma         |   112.95 |   6.23 |
| Gamma         |   208.37 |  10.41 |

* mean energies are listed for beta particles

Source: www.nndc.bnl.gov

Lutetium ( 177 Lu) emits beta ( β ) particles of moderate maximum energy (0.498 MeV) with a maximum tissue penetration of approximately 2 mm. The beta-emission of  177 Lu is accompanied by several gamma -photons with energies of 208 keV and 113 keV, which makes it useful for single photon emission computed tomography (SPECT) imaging and, hence, allows dosimetry.

This solution is produced and released by Eckert &amp; Ziegler Radiopharma GmbH in full compliance with GMP standards and requirements defined in the Ph. Eur. monograph 2798 Lutetium (177Lu) Solution for Radiolabelling .

Non-carrier added  177 Lu in the Theralugand preparation is produced via an indirect route, i.e., ytterbium ( 176 Yb) is irradiated to generate  177 Yb which decays with a half-life of 1.9 h to the intended  177 Lu.  177 Lu is then isolated from the irradiated target material.

## 2.3. Type of application and aspects on development

The legal basis for this application refers to Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application - specifically for a full but mixed application with the results of the nonclinical dosimetry study and supportive scientific literature.

No formal scientific advice was requested - for this procedure.

Several similar  177 Lu-RLT precursor products were approved using the same approach.

According to Annex 1 of Dir 2001/83/EC, as amended, in the specific case of a radiopharmaceutical precursor intended solely for radiolabelling purposes, the primary objective of the regulatory dossier shall be to present information, which would address the possible consequences of poor radiolabelling efficiency or in vivo dissociation of the radiolabelled conjugate, i.e. questions related to the effects produced in the patient by free radionuclide. Accordingly, a dosimetry study (EZ-Lu 177 ) was conducted by the applicant in rats to simulate the scenario of inadvertent direct precursor solution injection into a patient and elucidate the kinetics of the free  177 Lu. To provide further scientific background on the pharmacological, pharmacokinetic, and toxicological properties of lutetium and  177 LuCl3, the applicant conducted a systematic literature search in the public domain.

## 2.4. Quality aspects

## 2.4.1. Introduction

The finished product is presented as solution of radiopharmaceutical precursor containing 1 mL solution which contains 40 GBq lutetium ( 177 Lu) chloride at activity reference time (ART), corresponding to maximum 10 micrograms of lutetium ( 177 Lu) (as chloride) as active substance.

<div style=\"page-break-after: always\"></div>

The ART is set on the scheduled day of radiolabelling as indicated by the customer and can be up to 10 days starting from the day of manufacture.

Each 3 mL vial contains an activity ranging from 4 to 120 GBq at ART. The volume is 0.1 to 3 mL.

Each 10 mL vial contains an activity ranging from 12 to 200 GBq at ART. The volume is 0.3 to 5 mL.

The specific activity of the radiopharmaceutical precursor solution at ART is greater than 3 000 GBq/mg.

Other ingredients are diluted hydrochloric acid.

The product is available in colourless type I glass 3 mL vial with a V-shaped bottom or a colourless type I glass 10 mL vial with a flat bottom, closed with bromobutyl rubber stopper and aluminium crimp cap as described in section 6.5 of the SmPC. The vials are placed into a lead container with acrylic insert for protective shielding and packed in a metallic can and an outer carton.

## 2.4.2. Active Substance

## General information

The chemical name of the active substance is [ 177 Lu]Lutetium(III) chloride corresponding to the molecular formula [ 177 Lu]LuCl3. It has a relative molecular mass of 283.3 g/mol

Lutetium ( 177 Lu) chloride is a simple, inorganic substance, which does not form considerable chemical structures in solutions. The active substance is well soluble in aqueous milieu. The solubility in water at room temperature is approx. 1158 g/l.

The  177 Lu in the active substance is a non-carrier-added radionuclide from a non-fission source. It decays to stable hafnium ( 177 Hf) with a half-life of 6.647 days.  177 Lu is a medium-energy beta ( β -)-emitter that coemits low-energy gamma photons.

## Manufacture, characterisation and process controls

The active substance is manufactured by one manufacturing site.

The active substance is synthesised in 3 main steps:  transmutation of  176 Yb to  177 Lu, chromatographic separation, and recycling of  176 Yb.

The active substance lutetium ( 177 Lu) chloride is produced by neutron activation of stable ytterbium ( 176 Yb) followed by chemical and chromatographic separation from the irradiated target material. The manufacture does not contain any organic chemical synthesis. The separation steps are performed in dedicated, specially designed lead-shielded and air-tight boxes providing a controlled environment to ensure radiation safety and to avoid contaminations of the active substance. Adequate in-process controls are applied during the synthesis.

The specifications and control methods for intermediate products, starting materials and reagents have been provided and they are satisfactory.

The active substance is lutetium ( 177 Lu) chloride and it is not susceptible to chemical degradation.

The described manufacturing methods of Lutetium-177 are consistent and suitable. The applicant set a frame for the irradiation conditions at the nuclear research reactors which are applicable for each irradiation site. This frame contains a common target geometry, an optimal neutron energy spectrum for the  176 Yb(n,γ) 177 Yb reaction, a minimum neutron flux rate, a maximum irradiation time and a minimum cooling down time.

<div style=\"page-break-after: always\"></div>

The formation of chemical synthesis by-products can be excluded as the active substance is not of synthetic origin. Impurities in the active substance could theoretically arise from the irradiation process of the target material or may be introduced by the substances and materials used in the manufacturing (the target material itself, mobile phase components, solvents, further materials). The risk of the formation or introduction of impurities via these routes is discussed in detail. In conclusion, the risk is however considered very low due to high quality grades and thorough quality control of all materials as well as due to the purification effect of the HPLC step in the manufacturing process.

The characterisation of the active substance and its impurities are in accordance with the EU guideline on chemistry of new active substances. Potential and actual impurities were well discussed with regards to their origin and characterised.

The active substance, dried lutetium ( 177 Lu) chloride, is processed to the finished product without considerable storage times. Therefore, no container closure system is used.

## Specification

Since the active substance is processed by dissolution into the finished product without leaving the production line and without any substantial storage or holding times, it is not considered as isolated. Therefore, in line with the Guideline on Radiopharmaceuticals, quality control of the active substance is covered by the quality control of the finished product.

## Stability

The active substance, dried lutetium ( 177 Lu) chloride, is processed to finished product without storage.

Therefore, a stability evaluation of the active substance is not applicable in this case.

## 2.4.3. Finished Medicinal Product

## Description of the product and Pharmaceutical development

The finished product is presented as clear colourless solution.

The goal of the finished product development was to create a lutetium ( 177 Lu) chloride solution for radiolabelling that complies with the provisions of the Ph. Eur. monograph 2798 (current version) and provides suitable conditions for efficient radiolabelling reactions.

The physico-chemical characteristics of the active substance are well known. Lutetium ( 177 Lu) chloride is not susceptible to chemical degradation and can be (re-)dissolved in diluted hydrochloric acid.  177 Lu decays to stable hafnium ( 177 Hf) with a half-life of 6.647 days. Other instabilities or any incompatibilities are not expected.  177 Lu is an emitter of medium-energy beta-particles with a short tissue penetration range. The coemitted gamma photons can be employed also for single photon emission computed tomography (SPECT) imaging and dosimetry evaluations.

In line with Ph. Eur. monograph 2798 Lutetium ( 177 Lu) Solution for Radiolabelling, dilute hydrochloric acid is used as the only excipient in the medicinal product. Hydrochloric acid is a simple inorganic acid with low potential for unintended side reactions with carrier molecules to be radiolabelled by lutetium ( 177 Lu) chloride or their buffer components.

The excipient diluted hydrochloride acid is a well-known pharmaceutical ingredient and its quality is compliant with Ph. Eur. standards. There are no novel excipients used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC.

<div style=\"page-break-after: always\"></div>

The used low concentration / acidic strength of the diluted hydrochloric acid) is sufficient to maintain  177 Lu in the dissolved trivalent ion state but low enough to avoid extensive buffer and pH adjustments during radiolabelling procedures. Furthermore, hydrochloric acid is not affected by sterilisation by heat.

The diluted hydrochloric acid is manufactured from high-quality-grade concentrated hydrochloric acid and water for injection (Ph. Eur.) to limit the content of metal impurities which may impair the radiolabelling performance of the medicinal product.

The strength (i.e., activity concentration) of the active substance of 40 GBq/ml was chosen to allow a sufficient range of deliverable activities per packaging unit for radiolabelling of various potential carrier molecules.

The medicinal product manufacturing process is focused on production of the lutetium ( 177 Lu) chloride solution from the active substance, whereby the solution is eventually dispensed in ready-for-use, sterile aliquots with the intended activity concentration. The manufacturing is carried out in dedicated, specially designed lead-shielded and air-tight boxes that provide a controlled environment to ensure radiation safety and to avoid contaminations of the product. The manufacture consists of three process steps: dissolution of the active substance, dispensing of the obtained solution into appropriate vials, closure of the vials and sterilisation by heat. The suitability of the process was examined in validation studies provided.

The primary packaging is colourless type I glass 3 mL vial with a V-shaped bottom or a colourless type I glass 10 mL vial with a flat bottom, closed with bromobutyl rubber stopper and aluminium crimp cap. The material complies with Ph. Eur. requirements. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product. Extractables studies and leachables study performed during development support of the chosen primary packaging components for the finished product.

## Manufacture of the product and process controls

The finished product is manufactured by one manufacturing site. The GMP compliance of the site has been confirmed.

The manufacturing process consists of 3 main steps: dissolution of the active substance, dispensing of the obtained solution into appropriate vials, and closure of the vials and terminal sterilisation by heat. The process is considered to be a standard manufacturing process.

The sterility of the finished product is controlled by parametric release on the basis of the sterilisation process using heat to sterilise the product vials. The vials are sterilised by heat according to pharmacopeia standard conditions. The parametric release is done in compliance with the guideline on parametric release and provide supportive justification as demanded by the guideline on parametric release, demonstrating the reliability of the sterilisation by heat which justifies a parametric release on the basis of the heat sterilisation data temperature and time. In addition, the manufacturing site has sufficient experience in the sterilisation process using heat (for a comparable centralised authorised medicinal product), which further supports the application of parametric release.

Major steps of the manufacturing process have been validated in 3 commercial scale batches by a number of studies. It has been demonstrated that the manufacturing process is capable of producing the finished product of intended quality in a reproducible manner. The in-process controls are adequate for this type of manufacturing process.

<div style=\"page-break-after: always\"></div>

## Product specification

The finished product release specifications include appropriate tests for this kind of dosage form: appearance (visual), visible particles (visual), identification (gamma-ray spectrometry, physiochemical test, and thin layer chromatography), pH (pH indicator strip), chemical purity (ICP-OES), radionuclidic purity (gamma-ray spectrometry), radiochemical purity (thin layer chromatography), assay (dose calibrator/ ICP-OES), sterility (Ph. Eur.) and bacterial endotoxins (Ph. Eur.) which is in conformity with the applicable Ph. Eur. monograph no. 2798 (Lutetium ( 177 Lu) chloride solution for radiolabelling)

The purity profile of the lutetium ( 177 Lu) chloride solution is determined by the inherent purity profiles of the active substance and the excipient, with no degradation or interaction products to be expected from these simple inorganic substances during the manufacture or shelf-life of the finished product. The corresponding impurity risks are efficiently averted by adequate specifications and quality control measures as well as by the nature of the manufacturing process itself. No considerable impurities are also to be expected from the diluted hydrochloric acid, which is likewise subject to strict quality restrictions and through controls. All purity requirements of the Ph. Eur. monograph 2798 are included in the finished product specification and are readily met.

The ICH Q3D Guideline for Elemental Impurities is not applicable for radiopharmaceuticals.

A risk assessment concerning the potential presence of nitrosamine impurities in the finished product has been performed (as requested) considering all suspected and actual root causes in line with the 'Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products' (EMA/409815/2020) and the 'Assessment report- Procedure under Article 5(3) of Regulation EC (No) 726/2004- Nitrosamine impurities in human medicinal products' (EMA/369136/2020). Based on the information provided, it is accepted that there is no risk of nitrosamine impurities in the active substance or the related finished product. Therefore, no specific control measures are deemed necessary.

The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for testing has been presented.

Batch analysis results are provided for 3 commercial scale batches confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification.

## Stability of the product

Lutetium ( 177 Lu) chloride solution consists of simple, inorganic components. The short half-life (i.e., 6.647 days) of the radioisotope  177 Lu determines the shelf life of the solution. Therefore, the stability study was designed based on the recommendations of ICH guideline Q1A (R2) adapted to the short-lived radioactive nature of the product.

Stability data from 3 commercial scale batches of finished product stored for up to 10 days (starting from the manufacturing date) under storage at room temperature conditions are presented. The batches of medicinal product are identical to those proposed for marketing and were packed in the primary packaging proposed for marketing.

A bracketing design in line with the ICH guideline Q1D was applied to adequately cover the intended filling range of 4 - 200 GBq per vial and the two glass vial types that will be used for primary packaging (either 3 ml V-shaped vials or 10 ml flat bottom vials). All vials were closed with stoppers, crimped, autoclaved and

<div style=\"page-break-after: always\"></div>

then stored upside-down, so that the lutetium ( 177 Lu) chloride solution was constantly in contact with the stopper (worst-case scenario).

Samples were tested for appearance, pH, and purity (chemical, radionuclidic and radiochemical). The analytical procedures used are stability indicating.

In all three batches, the pH and the appearance of the lutetium ( 177 Lu) chloride solution did not change over the examined time. No considerable changes were also detected for all purity parameters, which remained well within the specified limits at the end of the stability study.

Based on available stability data, the proposed shelf-life of up to 10 days as stated in the SmPC (section 6.3) is acceptable.

From a microbiological point of view, unless the method of withdrawal from the vial or any insertion into the vial preclude the risk of microbial contamination, the radiopharmaceutical precursor solution should be used immediately.

If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.

## Adventitious agents

No excipients derived from animal or human origin have been used.

## 2.4.4. Discussion on chemical, pharmaceutical and biological aspects

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

## 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

## 2.4.6. Recommendations for future quality development

Not applicable.

<div style=\"page-break-after: always\"></div>

## 2.5. Non-clinical aspects

## 2.5.1. Introduction

177 LuCl3 is not intended to be administered directly to the patients. As a precursor, it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with  177 LuCl3.

A dosimetry study (EZ-Lu177) was conducted in rats to simulate the scenario of inadvertent direct precursor solution injection into a patient and elucidate the kinetics of the free  177 Lu. In addition, to provide further scientific background on the pharmacologic, pharmacokinetic, and toxicologic properties of lutetium and 177 LuCl3, a systematic literature search in the public domain was submitted and is summarised in the sections below.

## 2.5.2. Pharmacology

177 LuCl3 is not intended to be administered directly to the patients. It is to be used only for the radiolabelling of appropriate carrier molecules that have been specifically developed and authorised for radiolabelling with 177 LuCl3 to be used for treatment.

177 Lu is a radioactive lutetium isotope that emits beta-particles upon decay to stable hafnium-177 ( 177 Hf) with a half-life of 6.647 days. Lutetium ( 177 Lu) emits beta ( β-) particles of moderate maximum energy (0.498 MeV) with a maximum tissue penetration of approximately 2 mm. The beta-emission of  177 Lu is accompanied by several gamma -photons with energies of 208 keV and 113 keV, which makes it useful for single photon emission computed tomography (SPECT) imaging and, hence, allows dosimetry.  177 Lu is broadly used as a therapeutic radionuclide for radiolabelling of specific carrier molecules, which are developed for targeted radiotherapies of various, predominantly oncologic, diseases.  177 Lu 3+  in form of a chloride solution for radiolabelling is particularly suitable for this purpose. Several characteristics of  177 Lu as a radionuclide, including low-energy beta-decay, a tissue penetration range of less than 1 mm and a comparatively long half-life of 6.647 days, result in pronounced advantages of this radioisotope in terms of logistics, handling, precise localised delivery of sufficient radiation dose to diseased tissue regions and low inadvertent radiation toxicity for patients.

## Physical chemistry:

| Structure of the active substance   | 177 LuCl 3         |
|-------------------------------------|--------------------|
| Molecular weight                    | 283.3 g/mol        |
| Solubility in water                 | soluble            |
| Stability                           | t 1/2 = 6.647 days |
| Radiochemical purity                | ≥ 99.0%            |

## 2.5.2.1. Primary pharmacodynamic studies

## Literature review

The 'primary pharmacodynamic function' of  177 LuCl3, or more specifically of  177 Lu 3+ , is to provide an isotope for stable and efficient labelling. Lanthanides tend to accumulate in tumours (Higasi, 1973). A strong affinity for tumour for  177 Lu, thulium ( 170 Tm), and  169Y b, that was comparable to that of  67 Ga has been shown (Hisada

<div style=\"page-break-after: always\"></div>

et al., 1973). All lanthanides in their 3+ oxidation state can be considered hard Lewis acid, and therefore, octadentate ligand DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and its modifications are the best chelators to stabilise them for the in vivo use (Maecke 2003). As all pharmacodynamic properties will be dependent of the medicinal product to be radiolabelled, the information below describes labelling specifics with the most commonly used carrier molecules in clinical practice.

Currently, two carrier molecules are considered to have proven clinical utility when used with  177 Lu, namely, 177 Lu-DOTATATE or  177 Lu-oxodotreotide and  177 Lu-PSMA-617 or  177 Lu-vipivotide tetraxetan. The former was approved in the EU/EEA under the brand name Lutathera for the treatment of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in September 2017, and the latter under the brand name Pluvicto was approved for the treatment of PSMA-positive metastatic castration-resistant prostate cancer in December 2022. Both active substances utilise DOTA-based chelators as carriers.

DOTA, while having slow complexation kinetics, demonstrated minimal metal release at pH 4.5 and intermediate stability even at pH 2.0 (Stimmel et al. 1998). DOTATATE, i.e. somatostatin (cyclic peptide hormone) analogue TATE coupled with the macrocyclic chelator DOTA, is one of the most commonly used carrier molecules radiolabelled with  177 Lu in the current clinical practice.  177 Lu-DOTATATE labelling efficiency was shown to depend on the molar ratio, increasing with the excess of ligand and reaching over 99% at 5fold ligand excess (Pawlak et al. 2007).

PSMA-617 is a urea-based PSMA-targeting small molecule that has shown superior binding affinity to PSMA compared to other PSMA-targeting molecules. Following DOTA-mediated radiolabelling with  177 Lu, no free activity was detected at 1 h and 24 h postlabelling, while only &lt;0.4% and &lt;0.6% of free 177 Lu were detected after 48 h and 72 h of incubation, respectively, in PBS and human serum (Benesova et al. 2015).

## 2.5.2.2. Secondary pharmacodynamic studies

## Literature review

A few investigations have been identified in literature that assessed potential effects of lutetium on GABA channels (reversible stimulation of GABA-induced chloride channels in the primary culture of rat dorsal root ganglion neurons, Ma et al. 1993) and Ca 2+  flow and accumulation (elevated Ca 2+  concentrations in tissues following administration of LuCl3 to rats, Nakamura et al. 1997).

## 2.5.2.3. Safety pharmacology programme

Since  177 LuCl3 solution is not intended to be administered directly to the patients, no safety pharmacology testing was carried out by the applicant.

## 2.5.2.4. Pharmacodynamic drug interactions

No pharmacodynamic drug interaction studies have been conducted.

## 2.5.3. Pharmacokinetics

A non-clinical distribution study was carried out by the applicant in rats to obtain extrapolated human dosimetry data after accidental intravenous administration of  177 LuCl3 (study EZ-Lu177). Furthermore, published studies on  177 Lu pharmacokinetics are included in each relevant section below.

Overall, however, the PK of a  177 Lu-radiolabelled molecule will depend on the biological and chemical properties of the molecule to be radiolabelled and its mechanism of action in the human body.

<div style=\"page-break-after: always\"></div>

In the dosimetry study EZ-Lu177 carried out by the applicant, tissue samples were measured for the total radioactivity on a gamma counter, with exception of residual carcasses, which were analysed using SPECT/CT due to high tissue mass and radiation dose. Gamma counter and SPECT scanner were validated prior to the study conduct. No chemical analysis was carried out.

## Absorption

Study EZ-Lu177 investigated PK parameters of  177 Lu after IV injection with 30 MBq  177 LuCl3 to 18 female and 18 male healthy, mature Sprague-Dawley rats. At 5 min, 1 h, 12 h, 2 d, 7 d, and 35 d post-injection, the animals were euthanised, and their organs and tissues were measured ex vivo for total radioactivity. Additionally, 6 animals (3 female, 3 male) from the 35 days' group were imaged using SPECT/CT at 1 h, 12 h, 24 h, 2 d, 5 d, and 7 d post-injection for receiving longitudinal in vivo PK data within the same animal. Furthermore, blood samples were drawn from these animals for in vivo plasma kinetics prior to each SPECT/CT up to day 2 post-injection. To account for weight and activity differences between female and male rats and between individual rats, the SUV, a standardised uptake value adapted for both injected activity and body weight, was calculated.

Rapid absorption was observed upon intravenous administration of 30 MBq lutetium ( 177 Lu) chloride to rats, with the peak of lutetium ( 177 Lu) concentration in blood plasma reached within 12 min post-injection. See Figure 1 and Table 2.

<div style=\"page-break-after: always\"></div>

Figure 1:  177 Lu absorption following IV administration in rats: in vivo data (study EZ-Lu 177 )

Whole blood - in vivo

<!-- image -->

Table 2: Plasma pharmacokinetic parameters from rat ex vivo biodistribution data (study EZLu 177 )

|           | %IA/g   | %IA/g   | %IA/g       | SUV     | SUV    | SUV         |
|-----------|---------|---------|-------------|---------|--------|-------------|
| Parameter | Females | Males   | Unit        | Females | Males  | Unit        |
| Co        | 2.762   | 1.595   | %IA g-l     | 8.732   | 10.503 | SUV         |
| Cmax      | 2.376   | 1.512   | %IA g~      | 8.296   | 7.366  | SUV         |
| Tmax      | 0.161   | 0.206   | h           | 0.161   | 0.206  | h           |
| t1/2      | 0.625   | 2.580   | h           | 1.813   | 0.356  | h           |
| kel       | 1.108   | 0.269   | h-l         | 0.382   | 1.948  | h-l         |
| AUC0-.    | 5.387   | 7.497   | (%IA h) g   | 33.529  | 13.638 | (SUVh) gl   |
| CIT       | 0.186   | 0.133   | g (%IA h)-1 | 0.030   | 0.073  | g (SUV h)-1 |

## Distribution

## Literature

Accumulation of numerous radioactive rare earth elements in tumour tissues and several organs was directly compared to the accumulation of  67 Ga in Ehrlich's tumour-bearing dendrin mice.  177 LuCl3 was administered via IP injection at 50 mCi/mg (n=3 per group). Lutetium accumulated with a significant increase between 28 h to 48 h in tumour, some increase in bone and kidney, and a significant decrease over time in liver and spleen (Higasi et al. 1973).

Distribution of the radioactive  177 Lu following IP administration to the 3-4 weeks old female mice at single doses with activity ranging from 1 μ Ci to 60 mCi per kg body weight, supplemented by 0.5 mg/kg stable lutetium carrier, was reported by Müller et al. 1978. Skeleton averaged almost half of the injected dose compared to the soft tissues, while between 15% of radioactivity was detected in liv er and kidneys, and only 0.10.2% in the spleen and lungs in the first 24 h. While radioactivity decreased in s oft tissues over time, the skeleton dose remained stable up to 14 days postinjection. About 50% of the radionuclide was excreted in

<div style=\"page-break-after: always\"></div>

the first day. Biological half-lives averaged 5 days for the liver, spleen, and kidneys, and 50 days for skeleton.

Deposition in the organs and skeleton as well as possible late effects were further investigated in female mice by Müller et al. 1980. Various amounts of  177 Lu fused with KHSO4 and adjusted for pH with citrate were administered via IP injection, with the addition of 0.025 or 2 mg/kg body weight stable lutetium as carrier. 60% of the injected 177 Lu dose was detected in the skeleton 48 h post-injection. Over 14 days, gradual decrease was observed in both liver and skeleton values.

Study EZ-Lu177 investigated tissue distribution of  177 Lu after IV injection with 30 MBq  177 LuCl3 to SpragueDawley rats (for study design see above). While initially highest  177 Lu amounts were found in the liver, kidneys, and spleen (i.e. organs with high blood flow), after 12 h a continuous and steady increase was observed in the bones, in both males and females ( Figure 2 ). Male rats demonstrated significantly higher SUV than females for bone surface at 12 h (8.78±0.50 vs. 6.2±0.82, respectively; p &lt; 0.05) and at day 7 (9.9±0.43 vs. 6.5±0.31; p &lt; 0.05), while at day 35 this difference became less pronounced (11.4±0.35 vs. 10.8±0.75, respectively; p &lt; 0.05). Bone marrow showed moderate uptake with no significant sex differences, with a maximum SUV of 2.7±1.17 in females and 3.2±0.63 in males over time. In liver and spleen highest SUV values were observed on day 2 in males and on day 7 in females, after which the uptake decreased for both sexes markedly.

Figure 2:  177 Lu distribution following IV administration in rats (study EZ-Lu177)

<!-- image -->

25

20

15

37

SUV

177

B

Malerats-exvivo

O......

4

6

8

Time afterinjection (days)

In study EZ-Lu177 , a single dose of 30 MBq  177 LuCl3 was applied to both male and female rats to simulate clinical setting when the same not-weight-adjusted dose is applied to both female and male patients. Therefore, the values for %IA/g and %IA/organ were expectedly higher in female rats with substantiall y lower organ and body weights than in male rats. As a consequence, weight-adjusted SUV was considered more appropriate for direct comparison between the two sexes. Based on SUV, statistically significant sexdependent differences persisting for several time points were observed in  177 Lu uptake in the liver and spleen, with higher doses in females vs. males. At 35 days, however, there were no significant sex differences detected.

Another study from Literature (Nakamura et al. 1997) investigated differences in distribution, their influence on minerals' concentrations in various organs, and hepatotoxicity of seven nonradioactive rare earth elements, including lutetium. Rare earth elements were administered at low (5-10 mg/kg) and high (10-20

10

5

0

2

Femur

Bonemarrow

Liver

Spleen

28

35

<div style=\"page-break-after: always\"></div>

mg/kg) doses to the 4-week-old male Wistar rats (n = 5 per group) per IV injection in chloride form. Main lutetium accumulation sites were liver, bone, and spleen. Most of the rare earth elements (including lutetium) accumulated in bones were distributed into bone marrow. Significant differences were observed for lutetium concentration in serum (85.8±1.1% for 10 mg/kg and 83.9±0.9% for 20 mg/kg) vs. blood cells (14.2±1.1% for 10 mg/kg and 16.1±0.9% for 20 mg/kg).

In the study by Durbin et al. 1956,  177 Lu as a citrate complex was administered at doses of 7.3 to 29 μ Ci, with 0.5-1.9 μ g stable carrier, to the female Sprague-Dawley rats (at least 5 animals per group) via IM injection. In these experiments, over 60% of 177 Lu was deposited in the skeleton.

Based on study EZ-Lu177 , human absorbed doses of  177 Lu after IV injected  177 LuCl3 were estimated. It should be noted, however, that the absorbed organ doses and effective dose from the in vivo studies in rats could be different than those from the human studies because the physiology (e.g. blood flow rate) and metabolism of rodents are not the same as of humans. Another source of potential discrepancies is allometric scaling from animals to humans on the sole basis of body weight as applied in this study.

The estimated human radiation dose by using female rat data was higher compared to values when using male rat data. (see 2.6.2.2. Dosimetry). A source of difference, translating into differences in biodistribution volumes, are size and body weight: the mean body weight of female rats was 304±18 g, and, thus, approximately 200 g lower than that of male rats with 515±42 g. As both groups, in analogy to patient treatment, received the same 30 MBq activity of  177 Lu, female rats are expected to present with higher organ doses and a higher effective dose than male rats. Further potential explanation may be physiology-related sex-specific differences in organ uptake and function.

Higher accumulation of  177 Lu in the liver and spleen of female vs. male rats observed in the present study have not been reported for a different  177 Lu chloride product, EndolucinBeta (EndoculinBeta EPAR, EMA 2016). However, given the small sample size (n=2 per sex per group), statistical tests on group differences are difficult.

The effective dose for an adult with 73.7 kg body weight was reported as 0.534 mSv/MBq for EndolucinBeta, which is somewhat higher than the effective dose calculated from the applicant's data for  177 Lu chloride of 0.190 mSv/MBq for an adult. The applicant's data does correlate better with the effective dose reported for 177Lu-PSMA-617 (Pluvicto) ( Table 3 ).

For both EndolucinBeta and Theralugand, the organs with the highest organ doses are liver, bone, and spleen ( Table 3 ). Importantly, the addition of the carrier molecule significantly changes  177 Lu and, thus, radiation distribution for both Lutathera and Pluvicto bone activity is quite low compared to the organs participating in excretion such as liver and kidneys ( Table 3 ).

<div style=\"page-break-after: always\"></div>

Table 3: Comparison of the estimated organ dose coefficients and effective doses of  177 Lu products in humans (study EZ-Lu 177 )

|                            | mGy/MBq               | mGy/MBq                  | mGy/MBq                  | mGy/MBq               | mGy/MBq               |
|----------------------------|-----------------------|--------------------------|--------------------------|-----------------------|-----------------------|
|                            | EndolucinBeta'        | Theralugand (Study data) | Theralugand (Study data) | PluvictoTM 2          | Lutathera?            |
| Organ                      | Pooledmale and female | Female                   | Male                     | Pooledmale and female | Pooledmale and female |
| Osteogenic cells           | 2.1500                | N/A                      | N/A                      | N/A                   | 0.15                  |
| Endosteum(bonesurface)     | N/A                   | 0.2640                   | 0.1670                   | 0.0360                | N/A                   |
| Liver                      | 5.5600                | 2.2800                   | 1.0600                   | 0.0900                | 0.49                  |
| Spleen                     | 5.7300                | 2.6100                   | 0.9100                   | 0.0670                | 0.80                  |
| Kidneys                    | 0.3720                | 0.2760                   | 0.2890                   | 0.4300                | 0.65                  |
| Bone marrow (red)          | 0.5910                | 0.4790                   | 0.2930                   | 0.0350                | 0.03                  |
| Lungs                      | 0.0574                | 0.1120                   | 0.0804                   | 0.1100                | 0.03                  |
| Muscles                    | 0.0143                | 0.0358                   | 0.0336                   |                       | 0.03                  |
| Effectivedose60(mSv/MBq)   | N/A                   | 0.3040                   | 0.1430                   | N/A                   | N/A                   |
| Effectivedose103(mSv/MBq)4 | 0.5340                | 0.1900                   | 0.1900                   | 0.1200                | ND                    |

ForPluvicto and Lutathera,actual patient PK data were used forestimating absorbed dose coefficients

N/A=not applicable

1177Lu chloride

3(17Lu)Lutetium oxodotretotide (ligand for subtype2 somatostatin receptors)

(177Lu)Lutetium vipivotide tetraxetan (ligand to prostate specific membrane antigen,PSMA)

4Value averaged over both sexes asperICRPPublication103

## Literature

For a standard activity of 7,400 MBq usually applied for a single treatment cycle with  177 Lu-labelled tumourspecific molecules such as Pluvicto and Lutathera, organ doses of 7.84 Gy, 6.73 Gy, 2.15 Gy, 1.26 Gy and 2.15 Gy would be reached for liver, spleen, bone marrow, endosteum and kidneys in male patients, respectively, in case of an accidental direct IV application of Theralugand. For kidney, liver, bone and spleen, these doses are far below critical doses as usually assumed for these organs. Such, for kidneys, an organ dose of 28-40 Gy (depending on pre-existing risk factors) is considered as critical for subsequent kidney functional impairment and risk for kidney failure (Kratochwil et al. 2019). In a recent report on kidney dosimetry in prostate cancer patients undergoing treatment with  177 Lu-PSMA-617, the average kidney dose per administered activity was 0.67 ± 0.24 mGy/MBq (n=176; range, 0.21- 1.60 mGy/MBq). Thus, the estimated kidney dose of 0.276 (female) and 0.289 (male) mGy/MBq for Theralugand in case of an accidental direct administration or poor radiolabelling is in the lower range of kidney organ doses acquired by standard radioligand therapy with  177 Lu-PSMA-617 (Mix et al. 2022).

In contrast, for red bone marrow established tolerance limits are at 2 Gy (Emami et al. 1991). Therefore, based on the data of this study, in case of the accidental direct injection of a full standard dose of 7,400 MBq of Theralugand red bone marrow with an estimated organ dose of 2.15 Gy in males and 3.55 Gy in females would be the critical organ-at-risk. This would require strict clinical surveillance and medical support.

## Metabolism

Metabolism of free lutetium, independently of the radioactive status, has not been specifically investigated in animal studies. Radioactive  177 Lu decays to the stable isotope  177 Hf emitting beta-particles and gammaphotons.

<div style=\"page-break-after: always\"></div>

## Excretion

In literature, biliary excretion into the faeces was suggested to be major excretion route for all rare earth elements, including free lutetium, when injected per IV, while slight portions were rapidly excreted into urine (Nakamura et al. 1997). When administered into the muscle of rats, predominantly kidney excretion was reported for lanthanides, while liver excretion was observed with halflife of 10 to 20 days, with &lt; 10% remaining in the liver 2 months after injection (Durbin et al. 1956).

Lutetium ( 177 Lu) excretion occurred mainly via urine, with some faecal excretion observed.

## Pharmacokinetic drug interactions

No pharmacokinetic drug interaction studies relevant to the use of  177 Lu as a radiopharmaceutical precursor have been published.

## 2.5.4. Toxicology

No new toxicology studies have been performed. Theralugand is a radiopharmaceutical precursor and not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules.

## 2.5.4.1. Single dose toxicity

Literature submitted showed that single-dose studies have been carried out in mice and rats (see Table 4

and Table 5 ).

Table 4: Summary of single-dose toxicity studies in mice with lutetium

| Source            | Species/ Sex/Number   | Dose/Route                          | LD 50                                          | Major findings                                                                             |
|-------------------|-----------------------|-------------------------------------|------------------------------------------------|--------------------------------------------------------------------------------------------|
| Haley et al, 1964 | CF1 male Mice         | oral/up to 7590 mg/kg LuCl 3        | 7100 mg/kg corresponding to 197 mg/kg lutetium |                                                                                            |
|                   | CF1 male mice         | i.p./up to 372 mg/kg LuCl 3         | 315 mg/kg corresponding to 197 mg/kg lutetium  | Deaths, writhing, ataxia, laboured respiration, walking on toes with back arched, sedation |
| Bruce et al, 1963 | CF1 female mice       | i.p./0.5% and 0.1% of BW Lu-nitrate | 290 mg/kg corresponding to 108 mg/kg lutetium  | Depression leading to deaths Surviving animals showed generalised peritonitis              |

<div style=\"page-break-after: always\"></div>

Table 5: Summary of single-dose toxicity studies in rats with lutetium and other REEs

| Source               | Species/ Sex/Number   | Dose/Route                                                                                     | LD 50                                                                     | Major findings                                                                                                                                 |
|----------------------|-----------------------|------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|
| Bruce et al, 1963    | Rats                  | oral/no lutetium but other heavy lanthanides administered as nitrates oral/ rare earths oxides | About 3000 mg/kg N.D.                                                     | Low acute toxicity by the oral route                                                                                                           |
| Bruce et al, 1963    | SD female rats        | i.p./0.1% of BW Lutetium nitrate                                                               | 335 mg/kg corresponding to 125 mg/kg lutetium                             | Moderate toxicity, deaths animals had grossly distinct abdomen and limb oedemas, peritoneal inflammation, ascites fluid accumulation           |
| Bruce et al, 1963    | SD female rats        | i.p./1000 mg/kg Lu-oxide                                                                       | N.D.                                                                      | No signs of toxicity                                                                                                                           |
| Bruce et al, 1963    | SD female rats        | i.v./ heavy and light lanthanides                                                              | 30-60 mg/kg for heavy lanthanides 4.3 and 7.4 mg/kg for light lanthanides | Deaths occurred within 5 days after injection of light lanthanides, for the others mortality occurred throughout the 30-day observation period |
| Nakamura et al, 1997 | rats                  | i.v./50 mg/kg REEs                                                                             | N.D.                                                                      | Necrosis at the injection site, formation of zenobiotic granulomas in spleen, deaths                                                           |

Table 6: Summary of single dose studies with hafnium

| Source   | Species/   | Dose/Route/Hafnium   | LD 50   | Major findings   |
|----------|------------|----------------------|---------|------------------|
|          | Sex/Number |                      |         |                  |

<div style=\"page-break-after: always\"></div>

| Haley et al, 1962   | male CF1 mice/6 males and 6 females per group   | i.p./various doses of HfCl 4   | 112 mg/kg for hafnyl chloride corresponding to an LD50 of 76 mg/kg for hafnium   | Immediate urination and lethargy; deaths occurred within 24 h   |
|---------------------|-------------------------------------------------|--------------------------------|----------------------------------------------------------------------------------|-----------------------------------------------------------------|
| Haley et al, 1962   | rats                                            | Oral HfCl 4                    | 2362 mg/kg                                                                       | No signs of toxicity                                            |
| Haley et al, 1962   | Rats and cats                                   | i.v./ Hafnium-sodium mandelate | 75-100 mg hafnium/kg in rats 5.56 mg hafnium/kg in cats                          | No signs of toxicity                                            |

## 2.5.4.2. Repeat dose toxicity

Lutetium ( 177 Lu) chloride solution is intended for targeted radiotherapy after in vitro binding to different targeting agents. This application results in single or repetitive single dose administration in cycles with few individual administrations of the targeting radiocomplex. No single or repeated administration of free lutetium is intended, and the administration of the targeting radiocomplex does not lead to significant exposure to free lutetium, due to the tight binding to the complexing agent. The number of administrations and the number of cycles depends on the intended clinical use and is limited by the radioactive dose administered, leading to radiation-induced toxicity. Therefore, limited data are only available describing the repeated dose toxicity of non-complexed, non-radioactive lutetium and the decay hafnium.

No studies with lutetium were reported in mice.

Table 7: Summary of repeat-dose toxicity studies in rats with lutetium and hafnium

| Source            | Species/ Sex/Number                      | Dose/Route/LuCl 3                                        | NOEL                                                                  | Major findings                                                |
|-------------------|------------------------------------------|----------------------------------------------------------|-----------------------------------------------------------------------|---------------------------------------------------------------|
| Haley et al, 1964 | CRW Rats (6 male + 6 female per group)   | oral/0.01%, 0.1%, 1% within the diet for 90 days         | 1000 mg lutetium chloride/kg BW = 625 mg lutetium/kg BW at 1% in diet | No abnormal findings                                          |
| Haley et al, 1962 | CFN rats (6 male and 6 female per group) | Oral/0.01%, 0.1%, 1% within the diet for 12 weeks HfCl 4 | 100 mg hafnium chloride/kg BW = 55.5 mg                               | Liver changes/peri nuclear vacuolisation of parenchymal cells |

<div style=\"page-break-after: always\"></div>

| Source                       | Species/ Sex/Number   | Dose/Route/LuCl 3                                                                                                                               | NOEL                           | Major findings                                                                                                                            |
|------------------------------|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
|                              |                       |                                                                                                                                                 | hafnium/kg BW at 0.1% in diet  |                                                                                                                                           |
| Hinerman et al, 1954         | White rats (10)       | Oral/5 to 25 mg daily for 3 to 16 days s.c and i.m. / 10 mg, 15 mg, 20 mg for 4 weeks s.c. and i.m. /35 mg for 3 weeks hafnium sodium mandelate |                                | Oral: no lesions attributable to hafnium s.c. : failed to gain weight, abscesses at injection site bearing insoluble hafnium precipitates |
| BIBRA toxicity profile, 1994 | Guinea pigs           | Oral/Hafnium dioxide, up to 2000 mg/kg daily for 1 month                                                                                        | NO A EL: N.D. up to 2000 mg/kg | Increased liver weights, reduced kidney and spleen                                                                                        |

<div style=\"page-break-after: always\"></div>

## Interspecies comparison

Table 8: Relevant safety factors based on literature NOAEL data and body surface area

| Compound Species   | NOAEL dose, route of administration   | Corresponding total dose in mg/kg   | Human estimated dose 1   | Resulting safety factor per treatment 2   |
|--------------------|---------------------------------------|-------------------------------------|--------------------------|-------------------------------------------|
| Lutetium           |                                       |                                     |                          |                                           |
| Rat                | 1% of daily diet, oral                | 800                                 | 129 mg /kg               | Over 690,000                              |
| Cat 3 (CVS)        | 10 mg/kg, IV                          | 10                                  | 3.2 mg /kg               | Over 17,000                               |
| Cat 3 (CNS)        | 40 mg/kg, IV                          | 40                                  | 12. 9 m g/k g            | Over 69,000                               |
| Hafnium            |                                       |                                     |                          |                                           |
| Rat                | 1% of daily diet, oral                | 800                                 | 129 mg /kg               | Over 690,000                              |
| Ytterbium          |                                       |                                     |                          |                                           |
| Rat 4              | 1% of daily diet, oral                | 800                                 | 129 mg /kg               | Over 340,000                              |
| Cat 4 (CVS)        | 10 mg/kg, IV                          | 10                                  | 3.2 mg /kg               | Over 8,000                                |
| Cat 4 (CNS)        | 40 mg/kg, IV                          | 40                                  | 12. 9 m g/k              | Over 30,000                               |

1 Based on FDA Guidance 'Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers' (assumes 60 kg human weight).

<div style=\"page-break-after: always\"></div>

2 Based on the entire maximum treatment dose of  177 Lu-PSMA-617 of 44.4 GBq for 6 cycles of therapy in total.

Corresponds to 0.185 µg/kg metallic lutetium and hafnium and to 0.37 µg/kg metallic ytterbium. For all calculations human weight of 60 kg is assumed.

3 Rabbit conversion factor used for human estimated dose calculations as closest possible approximation.

4  Same NOEL values as for lutetium are assumed.

NOAEL is assumed to be equal to NOEL doses when only NOEL reported in literature.

CNS = central nervous system; CVS = cardiovascular system.

One study not discussed by the applicant in the repeated dose toxicity section but in the carcinogenicity section investigated the effects of long-term skeletal uptake of  177 Lu in mice (Müller et al, 1978). This study was performed to examine the incidence of osteosarcomas thought to be related to extended accumulation of lutetium in the bone tissue. The level of skeletal uptake increased with increasing dose of  177 Lu, along with increasing percentage of animals with osteosarcomas (ranging from 13% of animals administered 185 MBq/kg to 38% of animals administered 740 MBq/kg). Animals were given increasing dose s of  177 Lu (185 740 MBq/kg), and development of osteosarcomas was examined, including mean latency period and extent of survival. Latency period also seemed to decrease with increasing dose (from 645 days at 185 MBq/kg to 534 days at 740 MBq/kg).

## 2.5.4.3. Genotoxicity

No studies to evaluate the genotoxic potential of Theralugand have been submitted.

## 2.5.4.4. Carcinogenicity

No carcinogenicity studies have been conducted.

## 2.5.4.5. Reproductive and developmental toxicity

No studies on reproductive and developmental toxicity have been performed with Theralugand/  177 LuCl3, lutetium or hafnium and no data on reproductive and developmental toxicity are available in the literature.

No toxic effects on reproductive organs were observed in repeat dose toxicity studies after oral administration of lutetium chloride or hafnium chloride as a food admix for 90 days. Dosimetry data as calculated from organ distribution data indicate that lutetium does not accumulate in reproductive organs.

No studies in which the offspring (juvenile animals) are dosed and / or further evaluated have been conducted.

## 2.5.4.6. Local tolerance

As Theralugand is not intended for direct administration to humans, data on local tolerance have a limited significance for this application.  No local effects (intravenous or other route) are to be expected from the 177 Lu component of the final radiolabelled product, and the local tolerance of the final product will be tested with the final product only.

Nevertheless literature from studies on local tolerance with lutetium in animals have been submitted by the applicant and are summarised below.

<div style=\"page-break-after: always\"></div>

Table 9: Summary of local tolerance studies with lutetium

| Source              | Species/ Sex/Number   | Dose/Route/LuCl 3                                                        | Major findings                                                                                             |
|---------------------|-----------------------|--------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
| Haley et al, 1964   | 3 guinea pigs         | Intradermal, dilution up to 1:1000 Dilution 1:10 6                       | Necrosis, not complete reversed within 5 weeks Irritation index 2, healing accompanied by nodule formation |
| Haley et al, 1964   | 2 rabbits             | Eyes, 1:1 solution                                                       | Local irritation and delayed ulceration of the cornea, complete healing after 2 weeks                      |
| Haley et al, 1964   | rabbits               | Skin tolerance test by rubbing 0.5 g crystalline LuCl3 into abraded skin | Severe reaction, strong irritation peak after 24 h, healing with formation of scar tissue after 35 days    |
| Garrett et al, 1981 | mice                  | SC, 500 to 10000 µg/0.2 ml                                               | Local calcifications                                                                                       |

Table 10: Summary of local tolerance studies with hafnium

| Source            | Species/ Sex/Number   | Dose/Route/                                                                | Major findings                                                                           |
|-------------------|-----------------------|----------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
| Haley et al, 1962 | rabbits               | Eyes, 1 mg hafnium chloride                                                | Increase in blinking rate and redness of the conjunctiva which was reversible after 24 h |
| Haley et al, 1962 | rabbits               | Skin tolerance test by rubbing hafnium chloride crystals onto abraded skin | Strong local irritation with no healing within 14 days                                   |
| Haley et al, 1964 | Guinea pigs           | Intradermal injection (diluted solution 1:104 and 1:108)                   | Transient local irritation, complete remission within 7 days                             |

<div style=\"page-break-after: always\"></div>

## 2.5.4.7. Other toxicity studies

Table 11: Ex vivo studies with lutetium

| Source            | Species/ Sex/Number   | Dose/Route/LuCl 3                                                              | Major findings                                                                                                                                                                                                    |
|-------------------|-----------------------|--------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Haley et al, 1964 | Isolated rabbit ileum | 10 - 40 mg LuCl 3 + acetylcholine (2.5 µg) 10-40 mg LuCl 3 + nicotine (0.5 µg) | LuCl 3 induced an increasing depression of intestinal tonus and contractility of the ileum resulting in a non-reversible paralysis. This effect counteracted the spasmogenic effect of acetylcholine and nicotine |

Table 12: Studies evaluating hepatotoxicity of REEs

| Source               | Species/ Sex/Number               | Dose/Route/non- radioactive Lu and other REEs   | Major findings                                                                                                                                                                                           |
|----------------------|-----------------------------------|-------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Nakamura et al, 1997 | Male Wistar KY rats (3-5 animals) | i.v., 10 mg/kg LuCl 3 cerium, praseodymium      | LuCl 3 : no significant changes in hepatic lipids, GOT, GPT, serum bilirubin, total bile acids concentrations whereas cerium and praseodymium resulted in changes due to their accumulation in the liver |

Table 13: Studies evaluating nephrotoxicity of 177Lu-DOTATATE

| Source               | Species/ Sex/Number   | Dose/Route/                                                           | Major findings                                                        |
|----------------------|-----------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|
| Rolleman et al, 2007 | Tumour-bearing rats   | 278 + 555 MBq 177 Lu- DOTATATE                                        | Renal damage                                                          |
| Schuler et al, 2014  | Nude BALB/c mice      | 0.26, 2.4, 8.2 MBq 177 Lu- DOTATATE 90, 120, 150 MBq 177 Lu- DOTATATE | Minor morphological changes in kidney cortex Long-term renal toxicity |

<div style=\"page-break-after: always\"></div>

| Forrer et al, 2007   | Male Lewis rats   | 278 + 555 MBq 177 Lu- DOTATATE   | 555 MBq: severe damage of tubular function 278 MBq: histological findings comparable to the higher dose   |
|----------------------|-------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------|

## Studies on impurities

Theralugand is a sterile solution with 40 GBq/ml of  177 Lu in 0.04 mol/l hydrochloric acid. This solution is produced and released by Eckert &amp; Ziegler Radiopharma GmbH in full compliance with the GMP &amp; quality standards defined by the Ph. Eur. monograph 2798 Lutetium ( 177 Lu) Solution for Radiolabelling.

Theralugand is produced via an indirect route, i.e., the isotope ytterbium ( 176 Yb) is irradiated with neutrons to generate  177 Yb, which decays with a half-life of 1.9 h to the intended  177 Lu.  177 Lu is then isolated from the irradiated target material by preparative chromatography.

## 2.5.5. Ecotoxicity/environmental risk assessment

The applicant applied for a waiver with regards to the ERA. The submitted justification was that radiopharmaceuticals should be received, used and administered only by authorised persons in designated clinical settings. Their receipt, storage, use, transfer and disposal are subject to the regulations and/ or appropriate licenses of the competent official organisation. […] Any unused medicinal product or waste material must be disposed in accordance with local requirements. Finally, Product Information contains adequate warnings and precautions regarding handling and disposal.

Additionally,  177 Lutetium chloride is an inorganic salt for which an ERA was considered not required according to the Guideline on the Environmental risk assessment of Medicinal Products for Human use (EMEA/CHMP/SWP/4447/00\\_corr2).

## 2.5.6. Discussion on non-clinical aspects

177 LuCl3 is intended as a precursor for radiolabelling of carrier molecules specifically designed for this purpose and further use of the resulting conjugate in the clinic. The primary pharmacodynamic effect is thus a stable and efficient labelling.

At present, two  177 Lu-containing radiotherapeutics, Lutathera ( 177 Lu oxodotretotide or  177 Lu-DOTATATE) and Pluvicto ( 177 Lu vipivotide tetraxetan or  177 Lu-PSMA-617), are approved in the EU. Both of them have demonstrated highly efficient labelling of  177 Lu (more than 99%) and proved to be stable with minimal metal release.

Non-radioactive lutetium was reported to reversibly potentiate GABA response and to increase tissue accumulation of Ca 2+  in rats.

No safety pharmacology testing was carried out by the applicant which is considered acceptable as  177 LuCl 3  is not intended for direct use in patients. No pharmacodynamic drug interaction studies have been conducted for the same reason, which is also considered acceptable based on the same rationale.

Following IV administration to rats,  177 LuCl 3  was rapidly absorbed from plasma and distributed to the organs (see 2.5.3. Distribution). The methods of analysis in the so-called dosimetry study EZ-Lu177 have been considered suitable for their purpose and acceptable.

<div style=\"page-break-after: always\"></div>

Rapid absorption was observed upon intravenous administration of 30 MBq lutetium ( 177 Lu) chloride to rats, with the peak of lutetium ( 177 Lu) concentration in blood plasma reached within 12 min post-injection. Overall, the highest lutetium ( 177 Lu) uptake was detected in spleen, liver, and bone. In particular, at 1-hour postinjection, lutetium ( 177 Lu) predominantly accumulated in spleen and liver, reaching the highest values in these organs at day 2 in male and day 7 in female rats. Prominent accumulation in bone occurred at 12hours post-injection and further increased unsteadily up to day 35, obviously partly counteracted by the radioactive decay. Distribution of lutetium ( 177 Lu) to reproductive organs was rather low at all analysed postinjection time points.

Based on the results of the distribution study in the rat, the applicant estimated human absorbed doses of 177 Lu after accidental IV injection of  177 LuCl3 to patients. The doses reached in this case in the liver, spleen, endosteum and kidneys are below critical doses usually assumed for these organs. However, for red bone marrow established limits would be exceeded making it a critical organ-at-risk. This would require clinical monitoring and support. Nominal differences between EndolucinBeta and Theralugand observed in liver and spleen, i.e. organs with a high blood reservoir, may be attributed in part to differences in the handling of organs and blood and the respective losses during the autopsy procedure, but also are likely due to the small number of animals examined per time point. Nevertheless, both the organ doses and the effective doses are in a comparable order of magnitude for both  177 Lu chloride preparations.

Lutetium ( 177 Lu) excretion occurred mainly via urine, with some faecal excretion observed.

It should be noted, however, that the PK of a  177 Lu-radiolabelled molecule will also depend on the biological and chemical properties of the molecule to be radiolabelled and its mechanism of action in the human body.

No pharmacokinetic drug interaction studies relevant to the use of  177 Lu as a radiopharmaceutical precursor have been provided as none was published, it was considered acceptable.

The toxicity of non-radioactive lutetium chloride has been studied in different mammalian species and using different administration routes. The intraperitoneal LD50 in mice was found to be approximately 315 mg/kg. In cats, no pharmacological effects on respiration and cardiovascular function were observed up to a cumulative intravenous dose of 10 mg/kg. A high dose of 10 GBq of lutetium ( 177 Lu) chloride contains 2.4 μ g lutetium, corresponding to a human dose of 0.034 μ g/kg. This dose is approximately 7 orders of magnitude lower than the intraperitoneal LD50 in mice and more than 5 orders of magnitude lower than the NOEL observed in cats. Therefore, lutetium metal-ion toxicity of Theralugand-labelled medicinal products can be excluded. Toxicology is described by literature in accordance with Annex I Part III of Dir 2001/83/EC, as amended. In the specific case of a radio-pharmaceutical precursor intended solely for radio-labelling purposes, the primary objective shall be to present information which would address the possible consequences of poor radio-labelling efficiency or in vivo dissociation of the radio-labelled conjugate, i.e. questions related to the effects produced in the patient by free radionuclide. Thus, a summary of literature reviews laying the focus on the known toxic effects of lutetium was provided and is acceptable. Further, information on toxic effects of hafnium as the stable product after decay of lutetium was included in the original dossier. The main toxicological feature of radioactive lutetium chloride, concerns its uptake in bone and subsequent the development of osteosarcoma and its latency observed in rats and mice studies after long-term exposure, although Lutetium-177 is intended for short-term use. In terms of the safety associated with hafnium, theoretically the highest dose of hafnium would be the same as that of lutetium assuming that no lutetium is excreted before it decays completely. In view of this fact and the resulting safety factor per treatment, toxicity findings are considered of limited human relevance given the doses at which they occurred.

<div style=\"page-break-after: always\"></div>

Studies to evaluate the genotoxic potential or the carcinogenic potential of Theralugand have not been submitted as according to Annex 1 Part III of Dir 2001/83/EC, amended, studies to evaluate the genetic toxicity of the radionuclide of a radiopharmaceutical precursor intended solely for radiolabelling purposes are not considered necessary.

Based on the low exposure and the lack of accumulation in reproductive organs, no reproductive or developmental metal-based toxicity related to  177 Lu or  177 Hf is to be expected with Theralugand use, but the potential toxicity and distribution of the carrier molecule should be considered. Furthermore, radiation is a known mutagen and carcinogen, hence general radiation considerations apply. The lack of reproduction and developmental toxicity studies for Theralugand is acceptable for the same reason. Effects of lutetium (177Lu) chloride on male and female fertility have not been studied in animals. Low exposures could be demonstrated for male and female sexual organs. It cannot be excluded that lutetium (177Lu)-labelled medicinal products lead to reproductive toxicity including spermatogenetic damage in male testes or genetic damage in male testes or female ovaries.

Further information concerning fertility as well as the use of lutetium ( 177 Lu)-labelled medicinal products in women of childbearing potential, during pregnancy and breast-feeding will be specified in the Summary of Product Characteristics/package leaflet of the medicinal product to be radiolabelled.

Due to the radioactive nature of  177 Lu and thus its DNA reactivity,  177 LuCl3 would likely result in toxic reproductive and developmental effects.  177 Lutetium-labelled medicinal products are contraindicated in established or suspected pregnancy or when pregnancy has not been excluded. This is adequately reflected in the SmPC in 4.3 (Established or suspected pregnancy or when pregnancy has not been excluded (see section 4.6).) and 4.6 (The use of lutetium ( 177 Lu)-labelled medicinal products is contraindicated during established or suspected pregnancy or when pregnancy has not been excluded due to the risk of ionising radiation to the foetus (see section 4.3)).

No data has been presented for the use of  177 LuCl3 in juvenile animals. Due to the intended use of Theralugand for in vitro radiolabelling such studies are not considered necessary.

There is a limited amount of local tolerance data presented for lutetium and hafnium. Some local irritation to the eye and strong irritation of abraded skin only was with LuCl3.  Similar effects were observed with hafnyl chloride. The later irritation was considered related to the acidic nature of the compound.  Most of the local toxicities were reversible.

Application of LuCl3 on isolated rabbit ileum induced an increasing depression of intestinal tonus and contractability of the ileum resulting in a non-reversible paralysis counteracting the spasmogenic effect of acetylcholine and nicotine. As seen in the distribution study, an increased uptake of  177 Lu in liver and spleen was detected. However, evaluation of the non-radioactive LuCl3 up to the dose of 10 mg/kg in rats demonstrated no adverse effects on liver and hepatic enzymes. Nephrotoxicity is a known effect of  177 Lulabelled radiopharmaceuticals ( 177 Lu-DOTATATE and  177 Lu-PSMA). However, the effects on kidney damage could be counteracted by the addition of lysine.

The toxicological properties of lutetium ( 177 Lu)-labelled medicinal products prepared by radiolabelling with Theralugand prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled.

Of note, the drug product is a sterile 0.04 M HCl solution with controlled level of bacterial endotoxins and has a very low content of metal impurities (see also 2.4. ).

The applicant's waiver application with regards to the ERA was considered acceptable. As  177 Lutetium chloride

<div style=\"page-break-after: always\"></div>

is an inorganic salt and thus an electrolyte neither ERA studies nor a PBT screening are necessary according to the Guideline on the Environmental risk assessment of Medicinal Products for Human use (EMEA/CHMP/SWP/4447/00\\_corr2). Furthermore, the handling and disposal of radioactive materials are subject to strict regulations, hence it can be expected that the environment will not be exposed to 177 Lutetium chloride.

## 2.5.7. Conclusion on the non-clinical aspects

There are no objections against the approval of Theralugand from a non-clinical point of view.

## 2.6. Clinical aspects

## 2.6.1. Introduction

This is an application submitted under the legal basis of Article 8.3 of Directive 2001/83/EC, as amended with a full but mixed application (nonclinical dosimetry study and supportive scientific literature). The clinical aspects are therefore relying on a review of literature.

In line with the provisions of the Commission Directive 2001/83/EC on radiopharmaceutical precursors for radiolabelling, the main purpose of this clinical overview is to demonstrate the clinical utility of  177 Lu attached to relevant carrier molecules. While numerous carrier molecules to be radiolabelled with  177 Lu are currently in their preclinical and clinical development, in total only 2 molecules,  177 Lu-DOTATATE and  177 Lu-PSMA-617, are approved for marketing. Therefore, the selection of literature was limited to the currently established for routine clinical use  177 Lu-based applications, i.e., radioligand therapies with  177 Lu-DOTATATE and  177 Lu-PSMA (incl. PSMA-617 and PSMA-I&amp;T). The literature searches were carried out in PubMed and include literature up to March 27th, 2023. Search terms used were (\"Lu-177\") OR (\"177Lu\") OR (\"(177)Lu\") OR (\"Lu 177\") OR (\"177 Lu\") OR (\"LuCl3\") OR (\"Lutetium\" AND (\"177\" OR \"PSMA\")) OR (\"LuPSMA\") OR (\"Lu-PSMA\") OR (\"LuDOTA\") OR (\"Lu-DOTA\"). This search resulted in over 3,000 hits including articles containing nonclinical data (see 2.5. Non-clinical aspects).

Clinical articles have been then individually selected based on the following criteria for further review and discussion:

· completed clinical studies with 177Lu-DOTATATE, 177Lu-PSMA-617 or 177Lu-PSMA I&amp;T with main focus on efficacy and safety of the three radiolabelled compounds (as such, pure PK/dosimetry/computer modelling studies were excluded); for exclusively efficacy-f ocused studies, only most conclusive studies with ≥100 patients were included.

· clinical papers other than primary clinical studies reports, e.g., reviews and meta-analyses, that describe safety aspects specific to 177Lu-DOTATATE, 177Lu-PSMA-617 or 177Lu-PSMA I&amp;T.

• relevant clinical guidelines and treatment recommendations.

Reference lists of the originally extracted articles were examined for further relevant publications and the latter ones were similarly reviewed. In total, 99 publications have been identified as relevant based on the applied criteria and included in the application.

## GCP aspects

No clinical studies were performed and required for this type of RLT precursor. Therefore no GCP statement was provided.

<div style=\"page-break-after: always\"></div>

## 2.6.2. Clinical pharmacology

Lutetium ( 177 Lu) chloride n.c.a. is a precursor to be used for radiolabelling purposes in combination with other medicinal products consisting of a suitable linker (chelator) and a disease-specific carrier.

No clinical studies referring to clinical pharmacology for Lutetium ( 177 Lu) chloride n.c.a were provided in the application (see 2.6.3. Discussion on clinical pharmacology).

## 2.6.2.1. Pharmacokinetics

No clinical pharmacology studies were submitted with this application (see 2.6.3. Discussion on clinical pharmacology).

## 2.6.2.2. Dosimetry

The radiation dose received by various organs following intravenous administration of a lutetium ( 177 Lu)labelled radiopharmaceutical is dependent on the specific molecule being radiolabelled.

Information on radiation dosimetry of each different medicinal product following administration of the radiolabelled preparation is available in the Summary of Product Characteristics/package leaflet of the particular medicinal product to be radiolabelled.

The dosimetry tables below are presented in order to evaluate the contribution of non-conjugated lutetium ( 177 Lu) to the radiation dose following the administration of a lutetium ( 177 Lu)-labelled medicinal product or resulting from an accidental intravenous injection of Theralugand.

The dosimetry estimates are extrapolated from a rat distribution study. Single dose of 30 MBq Theralugand was used in the study. Post-injection time points for measurements were 5 min, 1 h, 12 h, 2 days, 7 days, and 35 days. Organ absorbed radiation doses (mGy/MBq) listed below for adult, 15-year, 10-year, 5-year, 1year and newborn male and female human models are derived from the distribution data in rats using IDACDose 2.1 v1.01 (for adults) and OLINDA/EXM v1.0 (for children and adolescents) software. Sex-specific effective dose coefficients (mSv/MBq) were calculated according to ICRP 60 (International Commission on Radiological Protection) provisions. The adult sex-averaged effective dose coefficient for accidentally injected lutetium ( 177 Lu) chloride, calculated according to ICRP 103 provisions, lays at 0.19 mSv/MBq.

In case of an accidental direct injection of lutetium ( 177 Lu) chloride, the organs with the highest absorbed doses based on rat data would be liver, spleen, bone, and kidneys.

Table 14: Estimated organ absorbed radiation doses and effective doses after inadvertent intravenous administration of 177LuCl3 in women, based on data collected in rats (n=18)

| Absorbed dose per administered unit of activity (mGy/MBq)   | Absorbed dose per administered unit of activity (mGy/MBq)   | Absorbed dose per administered unit of activity (mGy/MBq)   | Absorbed dose per administered unit of activity (mGy/MBq)   | Absorbed dose per administered unit of activity (mGy/MBq)   | Absorbed dose per administered unit of activity (mGy/MBq)   | Absorbed dose per administered unit of activity (mGy/MBq)   |
|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
| Organ (60                                                   | Adult 1 kg)                                                 | 15 years 2 (50                                              | 10 years 2 (30                                              | 5 years 2 (17 kg)                                           | 1 year 2 (10 kg)                                            | Newborn 2 (5 kg)                                            |
|                                                             |                                                             | kg)                                                         | kg)                                                         |                                                             |                                                             |                                                             |
| Adipose/residual tissue 0.029                               |                                                             | 0.274                                                       | 0.464                                                       | 0.771                                                       | 1.55                                                        | 4.14                                                        |

<div style=\"page-break-after: always\"></div>

| Adrenals                            | 0.199   | 0.184   | 0.266   | 0.365   | 0.565   | 0.549   |
|-------------------------------------|---------|---------|---------|---------|---------|---------|
| Bone marrow (red)                   | 0.479   | 0.229   | 0.394   | 0.799   | 1.97    | 6.73    |
| Bone surface                        |         |         |         |         |         |         |
| (endosteum)                         | 0.264   | ND      | ND      | ND      | ND      | ND      |
| Brain                               | 0.034   | 0.020   | 0.024   | 0.034   | 0.045   | 0.098   |
| Colon wall                          | 0.043   | 0.062   | 0.110   | 0.185   | 0.359   | 0.865   |
| Heart wall                          | 0.064   | 0.043   | 0.066   | 0.102   | 0.187   | 0.408   |
| Kidneys                             | 0.276   | 0.356   | 0.511   | 0.76    | 1.39    | 3.72    |
| Liver                               | 2.28    | 2.93    | 4.6     | 6.95    | 13.8    | 33.2    |
| Lungs                               | 0.112   | 0.177   | 0.253   | 0.392   | 0.782   | 2.14    |
| Muscle                              | 0.036   | 0.029   | 0.051   | 0.131   | 0.255   | 0.386   |
| Osteogenic cells                    | 6.66 2  | 6.53    | 10.7    | 18.1    | 43.6    | 142.0   |
| Ovaries                             | 0.094   | 0.102   | 0.316   | 0.566   | 1.35    | 2.94    |
| Pancreas                            | 0.071   | 0.076   | 0.136   | 0.189   | 0.372   | 1.08    |
| Salivary glands                     | 0.068   | ND      | ND      | ND      | ND      | ND      |
| Skin                                | 0.032   | 0.018   | 0.028   | 0.045   | 0.089   | 0.214   |
| Small intestine wall                | 0.064   | 0.075   | 0.132   | 0.220   | 0.43    | 1.08    |
| Spleen                              | 2.61    | 3.98    | 6.31    | 10.1    | 19.1    | 53.2    |
| Stomach wall                        | 0.115   | 0.058   | 0.091   | 0.152   | 0.3     | 0.851   |
| Thymus                              | 0.048   | 0.026   | 0.03    | 0.039   | 0.061   | 0.132   |
| Thyroid                             | 0.118   | 0.166   | 0.257   | 0.579   | 1.110   | 1.560   |
| Urinary bladder wall                | 0.047   | 0.02    | 0.034   | 0.055   | 0.109   | 0.256   |
| Uterus/cervix                       | 0.048   | 0.046   | 0.668   | 1.03    | 1.920   | 0.822   |
| Effective dose ICRP 60 (mSv/MBq)    | 3 0.304 | 0.325   | 0.55    | 0.91    | 1.97    | 5.27    |
| Effective dose ICRP 103 4 (mSv/MBq) | 0.19    | ND      | ND      | ND      | ND      | ND      |

ND = not determined as organ/tissue/data not available in OLINDA/EXM v1.0.

1  calculations made in IDAC-Dose 2.1 v1.01 software.

2  calculations made in OLINDA/EXM v1.0 software.

3  sex-specific doses derived according to ICRP Publication 60.

<div style=\"page-break-after: always\"></div>

4  sex-averaged dose derived according to ICRP Publication 103.

<div style=\"page-break-after: always\"></div>

Table 15: Estimated organ absorbed radiation doses and effective doses after inadvertent intravenous administration of  177 LuCl3 in men, based on data collected in rats (n=18)

| Absorbed dose per administered Organ   | Adult 1 (73 kg)               | 15 years 2 (50 kg)   | 10 years 2 (30 kg)   | 5 years 2 (17 kg)   | 1 year 2 (10 kg)   | Newborn 2 (5 kg)   |
|----------------------------------------|-------------------------------|----------------------|----------------------|---------------------|--------------------|--------------------|
| Adipose/residual tissue 0.031          | Adipose/residual tissue 0.031 | 0.258                | 0.436                | 0.724               | 1.46               | 3.89               |
| Adrenals                               | 0.172                         | 0.245                | 0.355                | 0.488               | 0.749              | 0.625              |
| Bone marrow (red)                      | 0.293                         | 0.174                | 0.297                | 0.594               | 1.46               | 5.0                |
| Bone surface                           | Bone surface                  | Bone surface         | Bone surface         | Bone surface        | Bone surface       | Bone surface       |
| (endosteum)                            | 0.167                         | ND                   | ND                   | ND                  | ND                 | ND                 |
| Brain                                  | 0.032                         | 0.024                | 0.029                | 0.04                | 0.053              | 0.115              |
| Colon wall                             | 0.053                         | 0.08                 | 0.14                 | 0.234               | 0.462              | 1.15               |
| Heart wall                             | 0.056                         | 0.068                | 0.105                | 0.166               | 0.301              | 0.605              |
| Kidneys                                | 0.289                         | 0.465                | 0.668                | 0.994               | 1.82               | 4.94               |
| Liver                                  | 1.06                          | 1.77                 | 2.77                 | 4.19                | 8.33               | 20.0               |
| Lungs                                  | 0.08                          | 0.157                | 0.225                | 0.348               | 0.696              | 1.91               |
| Muscle                                 | 0.034                         | 0.045                | 0.087                | 0.26                | 0.515              | 0.725              |
| Osteogenic cells                       | 5.27 2                        | 6.89                 | 11.3                 | 19.1                | 45.9               | 149.0              |
| Pancreas                               | 0.061                         | 0.088                | 0.171                | 0.228               | 0.483              | 1.58               |
| Salivary glands                        | 0.08                          | ND                   | ND                   | ND                  | ND                 | ND                 |
| Skin                                   | 0.103                         | 0.022                | 0.036                | 0.059               | 0.116              | 0.288              |
| Small intestine wall                   | 0.068                         | 0.105                | 0.184                | 0.307               | 0.607              | 1.56               |
| Spleen                                 | 0.91                          | 1.67                 | 2.65                 | 4.24                | 8.0                | 22.3               |
| Stomach wall                           | 0.113                         | 0.081                | 0.124                | 0.212               | 0.427              | 1.3                |
| Testes                                 | 0.035                         | 0.077                | 0.579                | 0.675               | 0.919              | 1.35               |
| Thymus                                 | 0.074                         | 0.056                | 0.057                | 0.068               | 0.098              | 0.206              |
| Thyroid                                | 0.144                         | 0.252                | 0.392                | 0.888               | 1.710              | 2.39               |
| Urinary bladder wall                   | 0.071                         | 0.031                | 0.052                | 0.083               | 0.166              | 0.407              |
| Effective dose ICRP 60 3 (mSv/MBq)     | 0.143                         | 0.255                | 0.496                | 0.769               | 1.55               | 4.11               |

<div style=\"page-break-after: always\"></div>

| Absorbed dose per administered unit of activity (mGy/MBq)   | Absorbed dose per administered unit of activity (mGy/MBq)   | Absorbed dose per administered unit of activity (mGy/MBq)   | Absorbed dose per administered unit of activity (mGy/MBq)   | Absorbed dose per administered unit of activity (mGy/MBq)   | Absorbed dose per administered unit of activity (mGy/MBq)   | Absorbed dose per administered unit of activity (mGy/MBq)   |
|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
| Organ                                                       | Adult 1 (73 kg)                                             | 15 years 2 (50 kg)                                          | 10 years 2 (30 kg)                                          | 5 years 2 (17 kg)                                           | 1 year 2 (10 kg)                                            | Newborn 2 (5 kg)                                            |
| Effective dose ICRP 103 4 (mSv/MBq)                         | 0.19                                                        | ND                                                          | ND                                                          | ND                                                          | ND                                                          | ND                                                          |

ND = not determined as organ/tissue not available in OLINDA/EXM v1.0.

1  calculations made in IDAC-Dose 2.1 v1.01 software.

2  calculations made in OLINDA/EXM v1.0 software.

3  sex-specific doses derived according to ICRP Publication 60.

4  sex-averaged dose derived according to ICRP Publication 103.

## 2.6.2.3. Pharmacodynamics

No clinical pharmacology studies were submitted with this application (see 2.6.3. Discussion on clinical pharmacology).

No interaction studies of lutetium ( 177 Lu) chloride with other medicinal products have been performed.

No information regarding genetic differences in PD response were provided.

## 2.6.3. Discussion on clinical pharmacology

The lack of biopharmaceutical studies and clinical pharmacology studies is considered acceptable. This approach is consistent with the one followed for the three other approved radiopharmaceutical products containing Lutetium ( 177 Lu) chloride as the precursor is not intended to be directly administered to the patient.

The clinical pharmacology of such radiopharmaceutical products dependent essentially on the carrier molecule labelled with Theralugand. Similarly, also the pharmacodynamics of a radiopharmaceutical precursor dependents on the carrier molecule and on the method of conjugation used to link it to the radioisotope.

In view of the pharmacological action, the only relevant aspect for the free  177 Lu is its stable binding to the carrier molecules which is mediated by various chelating agents. Octadentate ligand DOTA (1,4,7,10tetraazacyclododecane-1,4,7,10-tetraacetic acid) and its modifications are considered the best chelators to stabilise lanthanides, including lutetium, in their 3+oxidation state for the in vivo use (Maecke, 2003) and have been accordingly used for the authorised in the EU/EEA  177 Lu-DOTATATE and  177 Lu-PSMA-617 preparations.

However, according to annex I, point 2.2 of Directive 2001/83/EC as amended in Directive 2003/63/EC, for radionuclide precursors, 'the primary objective shall be to present information which would address the possible consequences of poor radio-labelling efficiency or in vivo dissociation of the radio-labelled conjugate, i.e. questions related to the effects produced in the patient by free radionuclide. In addition, it is also necessary to present relevant information relating to occupational hazards, i.e. radiation exposure to hospital staff and to the environment.'

<div style=\"page-break-after: always\"></div>

In this regard, the provided clinical pharmacology discussion is considered acceptable, same than for the pharmacokinetics of free Lutetium ( 177 Lu) due to poor radio-labelling efficiency or in vivo dissociation of the radiolabelled conjugate with its consequences in patients.

Pharmacokinetics of free  177 Lu injected as 30 MBq of  177 LuCl3 solution was investigated in the dosimetry study (EZ-Lu 177 ) conducted in rats by the applicant. The main purpose of this study was to estimate human radiation dosimetry in case of the accidental injection of unbound  177 Lu. Therefore, dosimetry extrapolation from rats to humans is presented in the clinical safety section (see 2.6.8. Clinical safety).

177 LuCl3 has no primary pharmacodynamic function and only very few data are available on the general pharmacodynamics of lutetium as a metal ion and  177 LuCl3, administered as a free soluble radioactive metal salt. Ionic lutetium in general appears to have no pharmacological function, but radioactive lutetium salts have been investigated for a few clinical applications.

No interaction studies of Lutetium ( 177 Lu) chloride with other medicinal products have been performed.

The pharmacodynamic properties of Lutetium ( 177 Lu)-labelled medicinal products prepared by radiolabelling with Theralugand, prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled.

## 2.6.4. Conclusions on clinical pharmacology

Adequate information was provided about  177 Lu 3+  biodistribution and dosimetry calculations, showing bone, liver, kidneys, red marrow and spleen as the main target organs.

It is accepted that the clinical pharmacology of Theralugand is dependent on the carrier molecule and therefore data specifically for Theralugand itself is not required. The relevant clinical pharmacology data with Theralugand will have to be submitted separately with the application for the different carrier molecules. Thus, the lack of studies in pharmacology for this application is acceptable. For the purpose of an application for a radiopharmaceutical for radiolabelling, the clinical pharmacology of Theralugand has been adequately addressed.

The same approach was in principle already agreed for the approval of other similar radiopharmaceutical products containing  177 Lutetium chloride in the identical indication during other centralised procedures (e.g. EMEA/H/C/003999 Endolucin Beta and EMEA/H/C/002749 Lumark) by CHMP.

## 2.6.5. Clinical efficacy

No original clinical efficacy studies were conducted by the applicant as information related to clinical efficacy obtained from the precursor alone is not considered relevant in the present case. Information on the clinical utility of the radiopharmaceutical precursor ( 177 Lu) when attached to appropriate carrier molecules has been provided. (See 2.6.1. Introduction).

Instead, as required for radiopharmaceutical precursors for radiolabelling purposes in the EU (Directive 2001/83/EC, Annex I, Part III section 2.2), information on the most important therapeutic applications has been provided, to demonstrate the clinical utility of  177 Lu when attached to relevant carrier molecules:

-  177 Lu-DOTATATE for treatment of SSTR positive Neuroendocrine tumours (NETs)
-  177 Lu-PSMA-617 for treatment of mCRPC.

## 2.6.5.1. Dose response study(ies)

The applicant did not submit studies on dose response (see clinical efficacy discussion).

<div style=\"page-break-after: always\"></div>

## 2.6.5.2. Clinical utility

## 2.6.5.2.1. 177 Lu-DOTATATE for treatment of SSTR positive Neuroendocrine tumours (NETs)

NETs can occur at any age, with the median age at diagnosis in the late fifth decade and an age-related incidence increase. The overall incidence of NETs was approximately 2.5 per 100,000 per year for the white population and approximately 4 per 100,000 per year for the black population in the US from 1992-1999, according to an analysis of the Surveillance, Epidemiology and End Results Registries of the National Cancer Institute (Modin et al., 2003).

In that same period, the overall 5year survival rate was 67.2%, but was much better for localised (78.2%) or regional (71.7%) disease than for distant (38.5%) disease. Additionally, the survival rate for patients with unstaged disease was only 48.3%. Thus , early detection and staging to allow appropriate treatment to reduce or prevent progression is highly desirable.

About two-thirds of NETs involve the GEP tract. The incidence of GEP-NETs increased in the last decades from 1.0 to 5.25/100,000 per year, with an estimated prevalence of 35/100,000 reported in 2014 (Grimaldi et al., 2014). Physicians' awareness, endoscopic screening and increased sensitivity of diagnostic tools may at least in part explain this growing trend.

Radiolabelled SST analogue therapy for the treatment of advanced, well-differentiated NETs was first described approximately 30 years ago (Horsch et al., 2016; Krenning et al., 1994; Krenning et al., 1993; Kwekkeboom et al., 2008). Initial efficacy results were based on very high doses of  111 In-DTPA0-octreotide, but more promising results were subsequently found with 90Y-DOTA0-Tyr3-octreotide ( 90 Y-DOTATOC) (Valkema et al., 2006) and with  177 Lu-DOTA0-Tyr3-octreotate ( 177 Lu-DOTATATE) (Kwekkeboom et al., 2008).

177 Lu-DOTA-conjugated somatostatin analogues have become an established procedure for the treatment of patients suffering from inoperable NETs overexpressing somatostatin receptors. The radiolabelled peptides 177 Lu-DOTATATE,  177 Lu-DOTATOC and  177 Lu-DOTANOC have the highest affinity to the subtype 2 of the somatostatin receptor family, which is also most commonly expressed by most NET (Breeman et al., 2016).

Additionally, the results of numerous uncontrolled prospective and retrospective studies involving NETs of different origin are summarised in the clinical AR in order to complete the available knowledge as documented in literature regarding the efficacy profile of  177 Lu-DOTATATE.

The standard protocol for  177 Lu-DOTATATE for treatment of SSTR-positive NETs comprised four cycles of treatment with an activity of 7.4 GBq per cycle (Kwekkeboom et al., 2008; Strosberg et al., 2017; Brabander et al., 2017). The cycles were repeated every 8 to 12 weeks. As the major organs at risk for unintended adverse effects are the kidneys and bone marrow, individualised protocols were developed which allow a cumulative absorbed dose of 23 Gy to the kidneys and of 2 Gy to bone marrow (Sandstrom et al., 2013).

This adaption allows for additional treatment cycles in selected patients and is essential to optimise therapy. Furthermore, therapy with  177 Lu-DOTATATE is generally combined with antiemetics and nephroprotective treatment.

## Comparative Clinical Trials with  177 Lu-DOTATATE

## NETTER-1

This was a large, representative open-label, randomised, comparator-controlled Phase 3 trial (NETTER-1) which investigated efficacy and safety of 4 cycles ¹⁷⁷Lu -DOTATATE in 231 patients with advanced,

<div style=\"page-break-after: always\"></div>

inoperable, well-differentiated SSTR-positive midgut NETs compared with long-acting octreotide administered intramuscularly.

A total of 231 patients (114 female, 117 male) were randomly assigned to receive either four cycles of ¹⁷⁷Lu -DOTATATE with an activity of 7.4 GBq (200 mCi) plus concomitant 30 mg octreotide (every 8 weeks combined, after last ¹⁷⁷Lu -DOTATATE cycle only octreotide administered every 4 weeks), or high-dose octreotide (60 mg) administered as a single treatment every 4 weeks. ¹⁷⁷Lu -DOTATATE was administered per intravenous infusion. Two out of 231 patients were randomly assigned after the primary PFS analysis data cutoff. Demographic and baseline disease characteristics were generally well balanced between the study groups.

In total, 200 (87%) of 231 patients entered long -term followup, including 101 (86%) of 117 patients in the ¹⁷⁷Lu -DOTATATE group and 99 (87%) of 114 patients in the control group.

The primary endpoint was PFS at the data-cutoff date; secondary endpoints included safety, OS and ORR.

## Progression-Free Survival

At the time of the data cutoff for the primary analysis (July 24, 2015; almost 3 years after study start), 23 events of disease progression or death had occurred in the ¹⁷⁷Lu -DOTATATE group vs. 68 such events had occurred in the control group (Strosberg et al., 2017).

At the datacutoff for the primary analysis, the median PFS had not yet been reached in the ¹⁷⁷Lu -DOTATATE group and was 8.4 months (95% CI, 5.8 to 9.1) in the control group (hazard ratio for disease progression or death with ¹⁷⁷Lu -DOTATATE vs. control, 0. 21; 95% CI, 0.13 to 0.33; p&lt;0.001), which represented a 79% lower risk of disease progression or death in the ¹⁷⁷Lu -DOTATATE group than in the control group. The estimated rate of PFS at month 20 was 65.2% (95% confidence interval [CI], 50.0 to 76.8) in the ¹⁷⁷Lu -DOTATATE group and only 10.8% (95% CI, 3.5 to 23.0) in the control group.

## Objective Response Rate

The ORR was defined as the percentage of patients who had a response according to RECIST (sum of partial responses and complete responses). Within the population of patients who could be evaluated for objective tumour response (n=201), the response rate wa s 18% in the ¹⁷⁷Lu -DOTATATE group vs. 3% in the control group (p&lt;0.001) (Strosberg et al., 2017).

## Overall Survival

The prespecified final OS analysis was conducted 5 years after the last patient was randomly assigned, when 142 deaths had occurred [16]. Median follow-up was 76.3 months (range 0.495.0) in the ¹⁷⁷Lu -DOTATATE group and 76.5 months (0.1-92.3) in the control group. Out of 142 patients who died there were 73/117 (62%) in the ¹⁷⁷Lu -DOTATATE group and 69/114 (61%) patients in the control group. Death due to disease progression was the leading cause of death in both groups.

Median OS was 48.0 months (95% CI 37.4 -55.2) in the ¹⁷⁷Lu -DOTATATE group and 36.3 months (25.951.7) in the control group. This longer median OS in the ¹⁷⁷Lu -DOTATATE group compared with the control group was clinically relevant, but not statistically sign ificant (HR 0.84 [95% CI 0.60 -1.17]; two-sided p=0.30).

## ILUMINET

These beneficial results of treatment with ¹⁷⁷Lu -DOTATATE were confirmed in a single-arm Phase 2 trial (ILUMINET) investigating personalise d ¹⁷⁷Lu -DOTATATE therapy (Sundlov et al., 2022). Safety and efficacy

<div style=\"page-break-after: always\"></div>

of individualised, dosimetrybased ¹⁷⁷Lu -DOTATATE treatment in 96 patients (42 female, 54 male) with NETs irrespective of origin was evaluated based on the hypothesis that treatment may be optimised by adjusting the number of cycles to the individually estimated renal BED.

The patients received cycles of 7.4 GBq of ¹⁷⁷Lu -DOTATATE preceded by antiemetics and co-administered with a kidney-protective amino acid infusion at 10±2-week intervals until a predefined radiation dose to the kidneys was reached. All patients were planned for treatment up to a cumulative renal BED of 27±2 Gy (step 1). Thereafter, patients with partial response or stable disease were offered further treatment up to a renal BED of 40±2 Gy (step 2). The median number of treatment cycles for all patients was 5 (range 1 to 9), with 51 patients (53%) receiving more than 4 cycles, and the median follow -up at the time of analysis was 42 months.

In patients with NETs of different origin, the objective tumour response 3 months after step 1 was 16% partial response (95% CI, 8.1 to 23%), 66% stable disease (95% CI, 56 to 75%), and 19% progressive disease (95% CI, 11 to 27%).

The median PFS and OS were 29 months and 47 months, respectively, with a 5year survival of 41% (95% CI, 31 to 54%). PFS and OS were significantly correlated with kidney dose, performance status, and Ki 67 levels but not with tumour origin.

Such, the median time to progression was 41 months (95% CI, 29 to 48 months) for all patients and 31 (95% CI, 22 to 46 months), 46 (95% CI, 26 months to not reached), and 48 months (95% CI, 36 months to not reached) for the renal BED groups &lt;25 Gy, 25-29 Gy, and &gt;29 Gy, respectively.

## 2.6.5.2.2. Metastatic Castration-Resistant Prostate Cancer

The current therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) includes several treatments to prolong OS, including docetaxel, androgen receptor-directed therapies such as abiraterone, and enzalutamide.

Among possible treatment options is the RLT, where a radionuclide is coupled to a ligand that specifically binds to the tumour cells. For treatment of mCRPC, the radionuclide  177 Lu is coupled to a PSMA analogue, e.g., PSMA-617 (see Pluvicto EPAR).

The knowledge about the efficacy of  177 Lu-PSMA for treatment of mCRPC is predominantly based on the comparative open-label Phase 3 trial VISION (Sartor et al., 2021) and the comparative Phase 2 trial TheraP (Hofman et al., 2021) (see below section relative to Comparative Clinical Trials with  177 Lu-PSMA). Additionally, the results of numerous prospective and retrospective studies summarised in 2.6.5.2.4. complete the efficacy profile (see Table 18).

The recommended RLT regimen for treatment of mCRPC consists of intravenous infusions of  177 Lu-PSMA for up to a total of 6 cycles unless there is disease progression or unacceptable toxicity (Pluvicto SmPC 2022).

## Comparative Clinical Trials with  177 Lu-PSMA

## VISION

In the VISION trial, the pivotal trial for MAA of Pluvicto, a total of 831 patients with mCRPC who were previously treated with at least one androgen-receptor-pathway inhibitor and one or two taxane regimens were randomised in a 2:1 ratio to receive either  177 Lu-PSMA-617 (7.4 GBq every 6 weeks for 4-6 cycles) plus protocol-permitted standard care (n=551) or standard care alone (n=280) (Sartor et al., 2021). Standardcare therapies could not include cytotoxic chemotherapy, systemic radioisotopes (e.g., radium-223 [ 223 Ra]),

<div style=\"page-break-after: always\"></div>

immunotherapy, or drugs that were investigational when the trial was designed (e.g., olaparib). These constraints were used because of a lack of safety data on combining the investigational drug with these agents. Permitted treatments included but were not restricted to the approved hormonal treatments (including abiraterone and enzalutamide), bisphosphonates, radiation therapy, denosumab, or glucocorticoid at any dose. The alternate primary end points were imaging-based PFS and OS. Key secondary end points were objective response, disease control, and time to symptomatic skeletal events. AEs during treatment were those occurring no more than 30 days after the last dose and before subsequent anticancer treatment.

The baseline characteristics of the patients were balanced between the groups. The median follow-up was 20.9 months. The analysis of OS included all the patients who had undergone randomisation (n=831), whereas imaging-based PFS and key secondary efficacy outcomes were analysed in a subgroup of these patients (n=581).

## Results

## Progression-Free Survival and Overall Survival

177 Lu-PSMA-617 plus standard care significantly prolonged, as compared with standard care, imaging-based PFS. Among the 581 patients in the analysis set, the median imaging-based PFS was 8.7 in the  177 Lu-PSMA617 group and 3.4 months in the control group (hazard ratio for progression or death, 0.40; 99.2% CI, 0.29 to 0.57; p&lt;0.001).

Among all 831 patients who underwent randomisation, median OS was 15.3 months in the  177 Lu-PSMA-617 group vs. 11.3 months in the control group (hazard ratio for death, 0.62; 95% CI, 0.52 to 0.74; p&lt;0.001).

## PSA Response

The proportions of patients with confirmed decreases in the PSA level of at least 50% from baseline were higher in the  177 Lu-PSMA617 group (46.0%) than in the control group (7.1%). Similarly, the proportions of patients with confirmed decreases in the PSA level of at least 80% were 33.0% versus 2.0% in the 177 LuPSMA-617 group and the control group, respectively. All other key secondary end points significantly favoured  177 Lu-PSMA-617.

## 2.6.5.2.3. Supportive Studies and Analyses with  177 Lu-DOTATATE

## Response to PRRT in NETs of Different Origin

## Study by Brabander et al. (2017)

Brabander et al. (2017) retrospectively investigated the treatment effect of ¹⁷⁷Lu -DOTATATE in patients with NETs of different origin. A group of 443 Dutch patients who were treated with a cumulative dose of at least 600 mCi (22.2 GBq) ¹⁷⁷Lu -DOTATATE was analysed for efficacy and survival.

Best ORR in the entire patient group was 39% - defined as the proportion of patients achieving CR and PR at follow-up according to the RECIST 1.1 criteria. In patients with midgut NETs and pancreatic NETs with progressive disease at baseline, radiologic di sease control was observed in 84% and 81%, respectively. Stable disease was reached in 43% of all NET patients, and progressive disease as treatment outcome was observed in 12% of patients and 5% of patients had non -evaluable treatment outcome. PFS and OS for all NET patients were 29 months [95% CI, 26 -33 months] and 63 months (95% CI, 55 -72 months), respectively. The median time to progression was 36 months (95% CI, 32 -40 months). Patients with a primary NET in the pancreas had the longest OS (see Figure 3).

<div style=\"page-break-after: always\"></div>

<!-- image -->

Source: Brabander et al. (2017) [19]

Note: Not shown are patients with primary tumour of the hindgut (n=12) and other foregut (n=12) due to the small number of patients. OS=overall survival

Figure 3 : Median OS in 419 NET patients treated with ¹⁷⁷Lu -DOTATATE by location of primary tumour: Study by Brabander et al. (2017)

For comparison with the NETTER-1 study described, patients with NETs of the midgut and progressive disease at baseline that received a cumulative dose of &gt;100 mCi (3.7 GBq) ¹⁷⁷Lu -DOTATATE were selected. The median PFS in this study was 24 months (95%CI, 18 -30 months), whereas it had not been reached in the ¹⁷⁷Lu -DOTATATE group in the NETTER-1 trial at data cutoff point. OS was 46 months (95% CI, 32 -60 months), which is comparable to the results of the NETTER-1 trial (OS: 48 months). The OS was significantly worse for patients with progressive disease at baseline (median 46 months) as compared with patients without progressive disease at baseline (median 82 months) (HR 0.49, 95% CI 0.31 -0.71; p&lt;0.01).

Tumour response also varied among NET types in the prospective observational study reported by GarskeRoman et al. (2018). Patients with small intestinal NETs showed a significantly lower ORR than patients with pancreatic and rectal NETs.

## SEPTRALU registry study

The SEPTRALU registry study evaluated data of 522 patients with pancreatic (35%), midgut (28%), bronchopulmonary (11%), pheochromocytoma/ paraganglioma (6%), other GEP (11%), and other non -GEP (9%) NENs (Mitjavila et al., 2023) . The patients were treated with 4 cycles of ¹⁷⁷Lu -DOTATATE administered at an activity of 7.4 GBq/cycles every 8 weeks. The best RECIST 1.1 responses were complete response in 3 patients (0.7%), partial response in 147 patients (33.2%), stable disease in 231 patients (52.1%), and tumo ur progression in 62 patients (14%), with activity conditioned by the tumour subtype, but with benefit in all strata (see Table 16 ). The overall disease control rate (responses and stabilisation s) was 86% (n=381). ORR and disease control rate broken down by tumour subtype was 42.4% and 84.8% in pancreatic NENs, 35.4% and 85.4% in other GEP -NENs, 31.5% and 78.9% in other non -GEPNENs, 28.6% and 77.6% in bronchopulmonary NENs, 28.2% and 93.5% in midgut, and 19.2% and 84.6% in

<div style=\"page-break-after: always\"></div>

pheochromocytoma/paraganglioma . Median PFS was 31.3 months (95% CI, 25.7 to 'not reached') in midgut, 30.6 months (14.4 to 'not reached') in pheochromocytoma/paraganglioma, 24.3 months (18.0 to 'not reached') in other GEP, 20.5 months (11.8 to 'not reached') in other non-GEP, 19.8 months (16.8 to 28.1) in pancreatic, and 17.6 months (14.4 to 33.1) in bronchopulmonary NENs. Median OS was 50.8 months (95% CI, 39.1 to 'not reached') in midgut NENs, 44.8 months (19.9 to 'not reached') in bronchopulmonary NENs, 34.2 months (30.4 to not reached') in pancreatic NENs, 33.6 months (21.0 to 'not reached') in other nonGEPs, and not-reached in other GEP-NENs and pheochromocytoma/paraganglioma (log-rank test, p=0.3).

Table 16: Response assessment according to tumour subtype: SEPTRALU registry study by Mitjavila et al. 2023

| Tumour type                       | Progressive disease   | Disease control   | Stable disease   | Partial response   | Complete response   | Total     |
|-----------------------------------|-----------------------|-------------------|------------------|--------------------|---------------------|-----------|
| N (%)                             | N (%)                 | N (%)             | N (%)            | N (%)              | N (%)               | N (%)     |
| pancreatic NENs                   | 24 (15.2)             | 134 (84.8)        | 67 (42.4)        | 66 (41.8)          | 1 (0.6)             | 158 (100) |
| midgut NENs                       | 8 (6.5)               | 116 (93.5)        | 81 (65.3)        | 34 (27.4)          | 1 (0.8)             | 124 (100) |
| bronchopulmonary NENs             | 11 (22.4)             | 38 (77.6)         | 24 (49.0)        | 14 (28.6)          | 0                   | 49 (100)  |
| pheochromocytomas/ paragangliomas | 4 (15.4)              | 22 (84.6)         | 17 (65.4)        | 5 (19.2)           | 0                   | 26 (100)  |
| other GEP-NENs                    | 7 (14.6)              | 41 (85.4)         | 24 (50.0)        | 17 (35.4)          | 0                   | 48 (100)  |
| other non-GEP-NENs                | 8 (21.1)              | 30 (78.9)         | 18 (47.4)        | 11 (28.9)          | 1 (2.6)             | 38 (100)  |
| Total                             | 62 (14.0)             | 381 (86.0)        | 231 (52.1)       | 147 (33.2)         | 3 (0.7)             | 443 (100) |

Source: Mitjavila et al. (2023) NEN=neuroendocrine neoplasm

## Study by Kwekkeboom et al. 2008

Of 310 GEP-NET patients evaluable for efficacy in a retrospective analysis, complete and partial tumour remissions occurred in 2% and 28%, respectively (see Table 17 ). Minor tumour response (decrease in size &gt;25% and &lt;50%) occurred in 16%. Median time to progression was 40 months. Median OS from start of treatment was 46 months, median OS from diagnosis was 128 months. Overall objective tumour response rate, comprisin g complete, partial, and minimal responses, was 46%.

Response rates in patients with gastrinomas, insulinomas, vasoactive intestinal peptide-secreting tumours and nonfunctioning pancreatic NETs were higher than in carcinoid tumour patients.

<div style=\"page-break-after: always\"></div>

Table 17: Response assessment according to tumour subtype: Study by Kwekkeboom et al. 2008

| Tumour subtype   | Complete Response   | Partial Response   | Minimal Response   | Stable disease   | Progressive disease   | Total                    |
|------------------|---------------------|--------------------|--------------------|------------------|-----------------------|--------------------------|
| N (%)            | N (%)               | N (%)              | N (%)              | N (%)            | N (%)                 | N (%)                    |
| 1 (1)            | 41 (22)             | 31 (17)            | 78 (42)            | 37 (20)          | 188 (100)             | Carcinoid                |
| 4 (6)            | 26 (36)             | 13 (18)            | 19 (26)            | 10 (14)          | 72 (100)              | Nonfunctional pancreatic |
| -                | 10 (32)             | 3 (10)             | 7 (23)             | 11 (36)          | 31 (100)              | Unknown origin           |
| -                | 5 (42)              | 4 (33)             | 2 (17)             | 1 (8)            | 12 (100)              | Gastrinoma               |
| -                | 3 (60)              | -                  | 1 (20)             | 1 (20)           | 5 (100)               | Insulinoma               |
| -                | 1 (50)              | -                  | -                  | 1 (50)           | 2 (100)               | VIPoma                   |
| 5 (2)            | 86 (28)             | 51 (16)            | 107 (35)           | 61 (20)          | 310 (100)             | Total                    |

Source: Kwekkeboom et al. (2008) VIPoma=vasoactive intestinal peptide-secreting tumour

## Study by Demirci et al. 2018

In patients treated with at least 3 cycles of ¹⁷⁷Lu -DOTATATE, the estimated mean OS was longest in patients with a primary tumour originating from pancreas (57.4 months), followed by nonpancreatic GEP-NETs (57.3 months), pheochromocytoma and paraganglioma (51.8 months), unknown primary (48.3 months), lung (44.3 months) and other sites (25.4 months) (Demirci et al., 2018).

## Study by Horsch et al. 2016

Patients with small NENs of small bowel had significantly increased survival (hazard ratio, 0.39; 95% CI, 0.18-0.87) compared to NENs of other locations as determined in a registry study with prospective follow-up (Horsch et al., 2016). Interestingly, PFS was not influenced by the location of the primary tumour in this study.

## Study by Baum et al. 2018

Similarly to the study above, in a retrospective analysis of 1048 patients with NENs, best OS was observed in patients with NENs of small bowel (69 months), which was statistically significant followed by carcinoma of unknown primary, others, pancreas and lung (Baum et al., 2018). In contrast to the studies described in this section, no significant differences in median PFS or OS were identified according to tumour origin in the ILUMINET trial (Sundlov et al., 2022).

## Treatment Response by Risk Factors, Progression-Free Survival and Overall Survival

As reported above, PFS as well as OS after treatment with ¹⁷⁷Lu -DOTATATE are dependent on the location of the primary tumour. However, several risk factors associated with shorter survival were identified in retrospective analyses.

<div style=\"page-break-after: always\"></div>

The OS was significantly shorter in NEN patients with liver or bone metastases at baseline (Brabander et al., 2017). Also, patients with increased ALP levels (&gt;120 IU/L) and patients with extensive disease as scored with the OctreoScan had a worse prognosis.

In studies evaluating personalised dose regimens, there were significant differences in OS and PFS according to renal BED, ECOG performance status and Ki 67 levels (Sundlov et al., 2022). The median time to maximum response was 18 months for all patients (95% CI, 16 to 22) and 13 (95% CI, 11 to 19 months), 23 (95% CI, 18 to 31 months), and 28 months (95% CI, 17 to 36 months) for the three renal BED groups &lt;25 Gy, 25-29 Gy, and &gt;29 Gy, res pectively. The median time to progression was 41 months (95% CI, 29 to 48 months) for all patients and 31 (95% CI, 22 to 46 months), 46 (95% CI, 26 months to not reached), and 48 months (95% CI, 36 months to not reached) for the renal BED groups &lt;25 G y, 25-29 Gy, and &gt;29 Gy, respectively.

Type of radionuclide, location of primary tumour and proliferation index were identified as risk factors of OS and PFS in a registry study with prospective follow-up (Horsch et al., 2016). A total of 450 patients with progressive low- or intermediate grade NENs were included and followed for a mean of 24.4 months. Primary NENs were mainly derived of pancreas (38%), small bowel (30%), unknown primary (19%) or bronchial system (4%). The soma tostatin- analogues/chelators DOTATATE and DOTATOC were applied in most therapy cycles. ¹⁷⁷Lu was predominantly used as radionuclide, either alone (in 54% of patients) or in combination with ⁹⁰Y (in 29% of patients). ⁹⁰Y alone was used in 17% of patients. Median OS of all patients was 59 (95% CI ,49 to 68.9) months and PFS was 41 months. Both OS and PFS were significantly inferior in the patients treated with ⁹⁰Y solely compared to any PRRT with ¹⁷⁷Lu. Patients with small NENs of small bowel had significantly increased survival (hazard ratio, 0.39; 95% CI, 0.18e0.87) compare d to NENs of other locations. Grade II (hazard ratio, 2.06; 95% CI, 0.79 to 5.32) and grade III (hazard ratio, 4.22; 95% CI, 1.41 to 12.06) NENs had significantly worse OS than grade I neuroendocrine neoplasms. In contrast, sex, age groups or number of previous therapies did not affect survival.

In a retrospective analysis of 1048 patients with NENs, best OS was achieved by a combination of ⁹⁰Y - and ¹⁷⁷Lu - for PRRT (Baum et al., 2018) . Shortest survival was observed in patients treated exclusively with ⁹⁰Y, while treatment with solely ¹⁷⁷Lu resulted in an intermediate survival between the two extreme curves.

Extended liver metastases (liver tumour burden &gt;50%), more than one line of chemotherapy, and elevated alkaline phosphatase &gt;2x the upper normal limit were independent risk factors for both progression and death (Fross-Baron et al., 2021). Presence of bone metastases and elevated CgA levels were linked to shorter PFS. Surgery of the primary tumour and ECOG status 0 were independent positive prognostic factors for OS.

In addition, a significant predictor of poor PFS was a baseline plateletlymphocyte ratio ≥173.1 in 42 NET patients (Satapathy et al., 2022). However, this association was not significant on multivariate analysis.

Long-term survival outcomes were evaluated in a retrospective review of 104 patients with advanced NETs treated on 4 Phase 2 clinical trials with ¹⁷⁷Lu -DOTATATE (Kennedy et al., 2022). Median follow-up was 68 months. Median PFS and OS were 37 months and 71 months, respectively. The site of the primary tumour correlated with survival, with median OS of 81 months for intestinal origin, 73 months for lung origin, 69 months for pancreatic origin, 50 months for gastric origin, and 47 months for unknown origin. Similarly, the median PFS was 43 months for patients with intestinal primary tumours, 40 months for gastric, 33 months for pancreatic, 27 months for unknown, and 11 months for lung primary tumours.

5- and 10year OS were 62% and 29%, and 5 - and 10year PFS were 36% and 21%, respectively, demonstrating ¹⁷⁷Lu -DOTATATE can provide durable responses.

<div style=\"page-break-after: always\"></div>

## Objective Response Rate

ORR was affected by the NET type, the amount of radiation delivered to the kidneys, as well as the tumour proliferation rate (Garske-Roman et al., 2018). Of patients in whom the dose to the kidneys reached 23 Gy, 30.9% obtained an objective response (CR/PR) compared with 13% of patients in whom the dose to the kidneys did not reach 23 Gy for any reason (p&lt;0.0001). The response rate of 10.6% in patients wi th tumours with a low proliferation rate (Ki67 index ≤2%) was lower than in patients with higher prolif eration rates (30.6% and 31.3% for Ki -67 index 3 to 20% and &gt;20%, respectively). Furthermore, patients with small intestine NETs showed a significantly lower ORR than patients with pancreatic and rectal NETs.

Long-term response was evaluated in a retrospective analysis of 468 metastatic/advanced NET patients who underwent at least 2 cycles of ¹⁷⁷Lu -DOTATATE PRRT (Sitani et al., 2021). Median follow-up was 46 months, ranging from 4 to 97.6 months. Molecular imaging response (by PERCIST criteria) showed complete response in 29 patients (6%), partial response in 116 patients (25%), stable disease in 267 patients (57%) and progressive dis ease in 56 patients (12%). On RECIST 1.1 criteria, complete response was observ ed in 14 patients (3%), partial response in 126 patients (27%), stable disease in 282 patients (60%) and progressive disease in 46 patients (10%).

## Quality of Life

QoL of patients is one of the most important aspects of any cancer therapy. In the Phase 3 NETTER-1 trial, QoL was evaluated according to the European Organization for Research and Treatment of Cancer QoL questionnaires EORTC QLQ-C30 and G.I.NET-21 (Strosberg et al., 2018). EORTC QLQ-C30 was developed to assess the QoL of cancer patients. Patients completed the questionnaire at baseline and every 12 weeks until tumour progression. QoL scores were converted to a 100-point scale according to European Organisation for Research and Treatment of Cancer instructions, and individual changes from baseline scores were assessed. Time to QoL deterioration was significantly longer in the ¹⁷⁷Lu -DOTATATE arm (n=117) versus the control arm (n=114) for the following domains: global health status (HR 0.406), physical functioning (HR 0.518), role functioning (HR 0.580), fatigue (HR 0.621), pain (HR 0.566), diarrhoea (HR 0.473), disease-related worries (HR 0.572), and body image (HR 0.425). Differences in median time to QoL deterioration were clinically significant in several domains: 28.8 months versus 6.1 months for global health status, and 25.2 months versus 11.5 months for physical functioning.

In a different study, EORTC QLQ-C30 questionnaires of a total of 265 patients were evaluated in a retrospective analysis. 241 of these patients completed the whole treatment and received 22.2 to 29.6 GBq of ¹⁷⁷Lu -DOTATATE. The baseline questionnaires were compared with questionnaires completed at the first visit after completion of therapy (Khan et al., 2011). Regardless of the treatment outcome, GHS/QoL, emotional and social functioning, insomnia, appetite loss, and diarrhoea improved significantly in the total group. These improvements were also seen in patients with bone metastases or a decrease of 50% or more in chromogranin A.

Improvement in the scores by at least 10 points was also analysed in a subgroup of patients with decreased GHS/QoL or symptoms at the start of therapy: in 36% of these patients, GHS/QoL improved after therapy; in 49%, fatigue; in 70%, nausea plus vomiting; in 53%, pain; in 44%, dyspnoea ; in 59%, insomnia; in 63%, appetite loss; in 60%, constipation; and in 67%, diarrhoea.

Additionally, there was no statistically significant deterioration in patients who had GHS/QoL 100, KPS 100, or no symptoms at the start. In patients with initial stable disease or remission after treatment, GHS/QoL and KPS decreased significantly when regrowth of the tumours occurred.

<div style=\"page-break-after: always\"></div>

QoL was evaluated in a study including 144 consecutive patients with histologically confirmed NETs using the European Organization for Research and Treatment of Cancer questionnaire (EORTC QLQ-C30) (Hamiditabar et al., 2017) . Among them, 132 were deemed evaluable by having at least 1 cycle of treatment with ¹⁷⁷Lu -DOTATATE and a post-treatment MRI or CT scan for assessment based on modified RECIST. Both quantitative and qualitative assessments of changes in QoL following PRRT were assessed. Out of 97 evaluable EORTCQLQs, 46 (47.4%) patients reported improvement, 47(48.4%) patients reported worsening, while 4 (4.1%) patients reported no change in their quality of life (p=0.59). Among patients who experienced improvement in their QoL, the average improvement f rom the baseline was 12% (range: 1 to 42) while patients who experienced worsening in QoL, the average of worsening from the baseline was 6.7% (range: -1 to -28).

## 2.6.5.2.4. Supportive Studies and Analyses with 177 Lu-PSMA

## TheraP study

PSA response rate, defined as the proportion of participants with PSA reduction of 50% or more from baseline, was the primary endpoint in the TheraP trial (Hofman et al., 2021). In this randomised, unblinded Phase 2 trial, a total of 200 men were randomly assigned in a 1:1 ratio to  177 Lu-PSMA-617 (6.0-8.5 GBq intravenously every 6 weeks for up to six cycles) or cabazitaxel (20 mg/m² intravenously every 3 weeks for up to ten cycles). Study treatment was received by 98/99 (99%) men in the 177 Lu-PSMA-617 group and by 85/101 (84%) men in the cabazitaxel group.

## PSA response

The characteristics of participants at baseline were similar in the two groups. PSA responses were more frequent among men in the  177 Lu-PSMA617 group (65/99, 66%) than in the cabazitaxel group (37/101, 37%) in the intention to treat analysis set (difference 29%; 95% CI 16 to 42; p&lt;0.0001). Using the 'by treatment received' analysis set, 66% of patients in the 177 Lu-PSMA617 group and 44% of patients in the control group had PSA responses (difference 23%; 9 to 37; p=0.0016).

## Radiographic Response

Among the 248 patients who had measurable target lesions according to RECIST, version 1.1, on independent central review at baseline, a complete response was noted in 17 of 184 patients (9.2%) in the 177 Lu-PSMA-617 group and in none of the 64 patients in the control group. A partial response was noted in 77 patients (41.8%) in the 177 Lu-PSMA617 group and in 2 (3%) in the control group.

## Study by Garske-Roman, 2018

A prospective observational study also showed that OS was longer in patients who reached an absorbed dose to the kidneys of 23 Gy compared to those patients who did not reach this dose (Garske-Roman et al., 2018).

Of 200 consecutive patients with metastasised SSTRpositive progressing NETs, 123 patients (61.5%) reached an absorbed dose to the kidneys of 23 Gy with 3 to 9 cycles during first-line therapy. In no patient a dose to the bone marrow of 2 Gy was reached. The best responses (according to RECIST 1.1) were a CR in 1 patient (0.5%), a PR in 47 (23.5%), stable disease in 135 (67.5%) and progressive disease in 7 (3.5%). Of patients in whom the dose to the kidneys reached 23 Gy, 30.9% obtained an objective respons e (complete response and partial response) compared with 13% of patients in whom the dose to the kidneys did not reach 23 Gy for any reason (p&lt;0.0001).

Median PFS was 27 months (95% CI 22 to 30 months) in all patients, 33 months in those in whom the absorbed dose to the kidneys reached 23 Gy vs. 15 months in those in whom it did not. Median OS was 43 months (95% CI 39 to 53 months) in all patients, 54 mon ths in those in whom the absorbed dose to the

<div style=\"page-break-after: always\"></div>

kidneys reached 23 Gy vs. 25 months in those in whom it did not. Median OS was 60 months in patients with a best response of partial response or complete response, 42 months in those with stable disease and 16 months in those with progressive disease.

## Tabulated summary of efficacy results in published studies conducted with  177 Lu-PSMA

Overview of the efficacy results per study in a chronologic order up to January 27th, 2023 is included in Table below:

Table 18: Efficacy results of studies with  177 Lu-PSMA for the treatment of mCRPC

| Study                       | Number of patients / Treatment   | Efficacy Measures            | Efficacy Measures    | Summary of results/Author's conclusions                                                                                                                                                                                                                                                                   |
|-----------------------------|----------------------------------|------------------------------|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                             |                                  | Median OS*                   | Median PFS/ PSA-PFS* |                                                                                                                                                                                                                                                                                                           |
| Ahmadzadehfar et al. (2017) | 100                              | 60 wks (95% CI: 47.3-72.7)   | -                    | Sixty- nine patients (69%) showed a PSA decline 2 months after the first cycle, 38 (38%) of which showed a PSA decline of ≥ 50%.                                                                                                                                                                          |
| Rahbar et al. (2017)        | 145                              | -                            | -                    | The overall biochemical response rate was 45% after all therapy cycles, whereas 40% of patients already responded after a single cycle. Elevated ALP and the presence of visceral metastases were negative predictors and the total number of therapy cycles positive predictors of biochemical response. |
| Rahbar et al. (2018)        | 104                              | 56.0 wks (95% CI: 50.5-61.5) | -                    | A total of 51 patients (49%) died during the observation period. Any PSA decline occurred in 70 (67%) and a PSA decline ≥50% in 34 (33%) of patients after the first cycle. Initial PSA decline ≥50%, initial Lactate dehydrogenase (LDH),                                                                |

<div style=\"page-break-after: always\"></div>

| Study                | Number of patients / Treatment           | Efficacy Measures                                                                                                                     | Efficacy Measures                                                                                                             | Summary of results/Author's conclusions                                                                                                                                                                                                                                                                                                              |
|----------------------|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                      |                                          | Median OS*                                                                                                                            | Median PFS/ PSA-PFS*                                                                                                          |                                                                                                                                                                                                                                                                                                                                                      |
|                      |                                          |                                                                                                                                       |                                                                                                                               | visceral metastases, second line chemotherapy or prior radium-223 did not have an effect on survival, whereas any initial PSA decline, initial alkaline phosphatase <220 U/L and cumulative injected activity ≥18.8 GBq were associated with a longer survival. PSA decline ≥20.87% was the most noticeable cut-off prognosticating longer survival. |
| Barber et al. (2019) | 167                                      | 10.7 months (95% CI: 7.9 - 13.5 months) for T-pre-treated patients and 27.1 months (95% CI: 18.4 - 35.8 months) for T-naive patients. | 6.0 months (95% CI: 3.2-8.8 months) for Tpre- treated patients and 8.8 months (95% CI: 7.1-10.6 months) for T-naive patients. | PSA response assessment was evaluable in 132 patients and seen in 25 of 62 (40%) T -pre-treated patients and 40 of 70 (57%) T -naive patients.                                                                                                                                                                                                       |
| Gafita et al. (2020) | Response (≥30% decline) in PSA at 6 wks. | 16.7 month; (95% CI, 14.4 - 19.0)                                                                                                     | 7.1 month; (95% CI, 4.7-9.5)                                                                                                  | A ≥30% decline in PSA at 6 wks. was associated with longer OS than stable PSA (P=0.007) or PSA progression (P<0.001).                                                                                                                                                                                                                                |
| Gafita et al. (2020) | Progression (≥25%                        | 6.5 month; (95% CI, 5.2-7.8)                                                                                                          | 1.2 month; (95% CI, 1.1-1.3)                                                                                                  | A ≥30% decline in PSA at 6 wks. was associated with longer imaging-                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| Study               | Number of patients / Treatment                        | Efficacy Measures              | Efficacy Measures            | Summary of results/Author's conclusions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------------------|-------------------------------------------------------|--------------------------------|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                     |                                                       | Median OS*                     | Median PFS/ PSA-PFS*         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                     | increase) PSA at 6 wks.                               |                                |                              | based PFS than stable PSA (P=0.01) or PSA progression (P<0.001). Patients with a ≥30% decline in PSA at 6 wks. also had a lower risk of imaging based progression than patients with stable PSA (hazard ratio [HR], 0.60; 95% CI, 0.38 - 0.94) (P=0.02), whereas patients with PSA progression had a higher risk of imaging based progression than patients with stable PSA (HR, 3.18; 95% CI, 1.95 -5.21) (P<0.001).                                                                                                                                                                                                                                                                                                             |
|                     | Stable (<30% decline and <25% increase) PSA at 6 wks. | 11.8 month; (95% CI, 8.6 - 15) | 2.0 month; (95% CI, 0.1-4.1) | based PFS than stable PSA (P=0.01) or PSA progression (P<0.001). Patients with a ≥30% decline in PSA at 6 wks. also had a lower risk of imaging based progression than patients with stable PSA (hazard ratio [HR], 0.60; 95% CI, 0.38 - 0.94) (P=0.02), whereas patients with PSA progression had a higher risk of imaging based progression than patients with stable PSA (HR, 3.18; 95% CI, 1.95 -5.21) (P<0.001).                                                                                                                                                                                                                                                                                                             |
| Yadav et al. (2020) | 90                                                    | 14 months                      | 11.8 months                  | Followed up over a median duration of 28 months. At 2- to 3-month interval after the first therapy and the end of the assessment, greater than 50% decline in PSA was observed in 32.2% and 45.5%, respectively. Radiographic response by diagnostic CT revealed partial remission in 23% (16/69), stable disease in 54% (37/69), and progressive disease in 23% (16/69) of patients. Molecular tumour response by PET Response Criteria in Solid Tumour 1 criteria revealed 19 (27.5%) of 69 patients with partial remission, 3 0 (43.5%) of 69 with stable disease, and 20 (29%) of 69 with progressive disease. The disease control rates according to the radiographic and molecular response were 77% and 71%, respectively. |

<div style=\"page-break-after: always\"></div>

| Study                                    | Number of patients / Treatment   | Efficacy Measures                                                                                                                                                     | Efficacy Measures                                                                                                                                                     | Summary of results/Author's conclusions                                                                                                                                                                                                                                                     |
|------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                          |                                  | Median OS*                                                                                                                                                            | Median PFS/ PSA-PFS*                                                                                                                                                  |                                                                                                                                                                                                                                                                                             |
| Yadav et al. (2021)                      | 121                              | 16 months (95% CI: 13-17)                                                                                                                                             | 12 months (95% CI: 10.3-13)                                                                                                                                           | The median follow-up duration was 36 months (6-72 months). Any PSA decline and PSA decline >50% was achieved in 73% and 61% of the patients, respectively. Multivariate analysis revealed only failure to achieve >50% PSA decline as a significant factor associated with a poor PFS.      |
| WARMTH Study Ahmadzadehfar et al. (2021) | 319                              | 11.6 months (95% CI: 10.3 - 12.9)                                                                                                                                     | -                                                                                                                                                                     | The extent of bone metastases and PSA response did not correlate significantly. Any PSA decline was observed in 73% patients; 44% showed a decline of ≥50%. The median OS of patient in the different subgroups was 18 months (20 lesions) and 8 months (diffuse involvement), respectively |
| Calais et al. (2021)                     | 71-included 43- results reported | Whole cohort- 14.0 months (95% CI 10.1 - 17.9 months), 6.0-GBq group- 15.8 months (95% CI 11.8 - 19.4 months), 6.0-GBq group- 13.5 months (95% CI 10.0 - 17.0 months) | 3.7 months in the overall study population (95% CI 2.0-5.4) 2.9 months in the 6.0- GBq group (95% CI 0.0-9.0) and 3.7 months in the 7.4- GBq groups (95% CI 1.9- 5.6) | The PSA response rates after 2 cycles and at any time were 11/40 (28%), 6/13 (46%), and 5/27 (19%), and 16/43 (37%), 7/14 (50%), and 9/29 (31%) in the whole cohort, the 6.0-GBq group, and the 7.4-GBq group, respectively.                                                                |

<div style=\"page-break-after: always\"></div>

| Study                             | Number of patients / Treatment       | Efficacy Measures                      | Efficacy Measures                                             | Summary of results/Author's conclusions                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------------------------------|--------------------------------------|----------------------------------------|---------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                   |                                      | Median OS*                             | Median PFS/ PSA-PFS*                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| TheraP Study Hofman et al. (2021) | 98/ 177 Lu-PSMA- 617 85/ cabazitaxel | -                                      | 5.1 months (3.4- 5.7) 5.1 months (2.8- 6.0)                   | PSA responses were more frequent among men in the ¹⁷⁷Lu -PSMA-617                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Kesavan et al. (2021)             | 100                                  | median overall OS has not been reached | 6- months (95% CI; 4.11-7.89)                                 | 54% achieved a PSA response. Disease control rate by PET/CT was 64% (29% stable disease, 34% partial response, and 1% complete response). Disease control by PET/CT was associated with an improved one-year OS compared to non-responders, median OS not- reached vs 10-months (p<0.0001; 95% CI:0.08 -0.44). Regarding haematologic toxicity, 11% experienced a grade ≥3 cytopenia (self-limiting).                                                                                         |
| Meyrick et al. (2021)             | 191                                  | 12 (5-18)                              | PSA PFS (n=132) 4 (3-8) months and PET/CT PFS 6 (3-10) months | A ≥50% PSA decline was observed in 89 (56%) patients, while any PSA decline occurred in 120 (75%) men. Better survival in responders. Predominantly lymph node metastatic disease and chemotherapy-naive status were significant pre-therapy factors associated with longer survival. Lower baseline PSA predicted a lower risk of death and disease progression. TEAEs included grade 3 or 4 haematological (12%), grade 1 or 2 renal (4.5%), and grade 3 or 4 other clinical events (5.7%). |

<div style=\"page-break-after: always\"></div>

| Study                             | Number of patients / Treatment                                                                                                                      | Efficacy Measures                                                                                                                                  | Efficacy Measures                                                                     | Summary of results/Author's conclusions                                                                                                                                                                                                                         |
|-----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                   |                                                                                                                                                     | Median OS*                                                                                                                                         | Median PFS/ PSA-PFS*                                                                  |                                                                                                                                                                                                                                                                 |
| VISION Study Sartor et al. (2021) | 551 patients/ 177 Lu-PSMA-617 plus protocol- permitted standard care ( 177 Lu-PSMA- 617 group) or 280 patients/ standard care alone (control group) | 15.3 vs. 11.3 months HR for death, 0.62 (95% CI, 0.52 - 0.74; P<0.001)                                                                             | 8.7 vs. 3.4 months HR for progression or death, 0.40 (99.2% CI, 0.29 - 0.57; P<0.001) | The median follow-up was 20.9 months. The incidence of AEs of grade 3 or above was higher with 177Lu-PSMA-617 than without (52.7% vs. 38.0%), but quality of life was not adversely affected.                                                                   |
| Seifert et al. (2021)             | 110                                                                                                                                                 | Lesion number, total tumour volume, and total lesion quotient were prognosticators of OS (HR=1.255, p=0.009; HR=1.299, p=0.005; HR=1.326, p=0.002) | -                                                                                     | In a stepwise backward Cox regression only LDH and total lesion quotient remained independent and statistically significant negative prognosticators of OS (HR=1.632, p=0.011; HR=1.239, p=0.024) in contrast to PSA value.                                     |
| Derlin et al. (2022)              | 208- initial 26- treatment extension                                                                                                                | -                                                                                                                                                  | 450 d (276- 1,742 d)                                                                  | During treatment extension (≤13 cycles), 50% of patients achieved an additional PSA decline (- 52%±34%; range - 1% to - 100%), with 8% of patients achieving a congruent PSA- based and imaging- based CR. Acute toxicity, including myelosuppression, was mild |

<div style=\"page-break-after: always\"></div>

| Study                                  | Number of patients / Treatment   | Efficacy Measures             | Efficacy Measures             | Summary of results/Author's conclusions                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|----------------------------------------|----------------------------------|-------------------------------|-------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                        |                                  | Median OS*                    | Median PFS/ PSA-PFS*          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                                        |                                  |                               |                               | (≤grade 2). Xerostomia and CKD became more common with                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| REALITY Registry Khreish et al. (2022) | 254                              | 14.5 (95%CI 11.5-17.5) months | 5.5 (95% CI 4.4 - 6.6) months | Best response was ≥50% PSA reduction in 52.0% of patients (132/254). In multivariable Cox proportional hazards modelling, response to the initial ≤2 RLT administrations was the strongest significant prognosticator related to OS (HR 3.7 [95% CI 2.5 -5.5], p<0.001). No RLT-related deaths or treatment discontinuations occurred; the most frequent RLT-related grade ¾ AEs were anaemia (18/254, 4.3%), and lymphopenia (7/254, 2.8%). RLT - related xerostomia, all grade ½, was noted in 53/254 (20,9%). |
| Mader et al. (2023)                    | 26                               | 29 (95% CI: 18 - 40) months   | 19 (95% CI: 15 - 23) months   | Further PSA decline of 33±28% during the extended treatment was observed in 21/26 (81%) patients, whereas 5/26 (19%) patients showed a PSA increase; correspondingly in 11/21 patients with an initial response to extended cycles, treatment was discontinued due to progressive disease, whereas six (23%) patients achieved low - volume residual disease. Two (8%) patients died without showing progression, and two (8%) patients are still under therapy.                                                 |

<div style=\"page-break-after: always\"></div>

* unless otherwise stated

177 Lu=Lutetium-177, RLT=radioligand therapy, OS=overall survival, PFS=Progression-free survival, wks.=week(s), d=day(s), CI=confidence interval, CKD=chronic kidney disease, AKD=acute kidney disease, HR=hazard ratio, OR=odds ratio,  223 Ra=Radium-223, LDH=Lactate dehydrogenase, HP=haematological parameters, CT=computed tomography, PET=positron emission tomography, PSA=prostate-specific antigen, PSMA=prostate-specific membrane antigen, SUVmax=maximum standardised uptake value.

## 2.6.6. Discussion on clinical efficacy

In accordance with the Annex 1 Part III of Directive 2001/83/EC, as amended , clinical information generated from clinical studies using the precursor itself is not considered to be relevant in the specific case of a radiopharmaceutical precursor intended solely for radiolabelling purposes. However, information demonstrating the clinical utility of the radiopharmaceutical precursor when attached to relevant carrier molecules shall be presented.

In support of the clinical utility of  177 Lu, the applicant performed a bibliographical search and presented comprehensive efficacy from published clinical trials (until January 2023), which have been conducted with 177 Lu-labelled tracer molecules. This approach is acceptable and consistent with previously centralised procedures for similar Lutetium ( 177 Lu) chloride radiopharmaceutical precursor products already marketed in the EU (e.g. EndolucinBeta).

Clinical utility is considered demonstrated in treatment of patients with neuroendocrine tumours using  177 Lulabelled somatostatin analogues as well as in the treatment of mCRPC using  177 Lu labelled PSMA compounds.

## 2.6.7. Conclusions on the clinical efficacy

It is concluded that there is enough evidence to support the clinical utility of  177 Lu coupled to suitable carrier molecules.

## 2.6.8. Clinical safety

No original clinical safety studies were conducted by the applicant. Safety is considered with respect to the radiation product itself and in order to provide data allowing an risk assessment in already well established 177 Lu-RLT indications (SSTR-pos NETS and mCRPC) approved in the EU. However, since Theralugand is only a precursor, specific risks of the intended administration of  177 Lu added to other carrier molecules may be also different. It will need an independent product specific benefit risk assessment in the intended indication.

## 2.6.8.1. Patient exposure

Patient exposure information is based on published studies with  177 Lu-labelled tracers.

## Accidental injection of free  177 Lu

No non-clinical studies investigated radiation dosimetry in case of the accidental injection of unbound  177 Lu to get a glance of the effects in patients. Extrapolating from the rat data, the estimated absorbed dose coefficients were the highest for the spleen (2.61 mGy/MBq vs. 0.91 mGy/MBq), liver (2.28 mGy/MBq vs. 1.06 mGy/MBq), bone marrow (0.48 mGy/MBq vs. 0.29 mGy/MBq), kidneys (0.28 mGy/MBq vs. 0.29 mGy/MBq), and bone surface (0.26 mGy/MBq vs. 0.17 mGy/MBq) for female vs. male adults. Hence, while numerical differences were observed between sexes in rats, the organs with the highest  177 Lu3+ accumulation were the same. (See 2.5. Non-clinical aspects).

<div style=\"page-break-after: always\"></div>

## Occupational and other inadvertent exposure

Theralugand is a subject to the restricted medical prescription and is intended for use in designated nuclear medicine facilities only. Furthermore, the in vitro radiolabelling procedure should only be handled by experienced specialists (see SmPC Section 4.2).

Data on radiation exposure to free  177 Lu was not available in literature. Studies investigating the radiation exposure of family members and of the public (Kurth et al., 2028; Levart et al., 2019) from patients treated with  177 Lu-PSMA-617 or  177 Lu-DOTATATE report that cumulative radiation doses in close proximity to the patients could potentially exceed over time the ICRP-recommended annual limit of 1 mSv per year in the absence of contact restrictions.

Although the actual risk is limited by the short distances which emitted β -particles can travel and their rather low tissue penetration depth (Hosono et al., 2018), the patients should be given precise recommendations upon release to further reduce inadvertent radiation exposure for others, especially for young children and pregnant women (Nelson et al, 2019).

Point-source approximation shows that the average dose rate experienced 20 hours after administration of a dose of 7.4 GBq Theralugand-labelled radiopharmaceutical (residual radioactivity 1.5 GBq) by a person at 1 meter distance from the patient's body centre with an abdominal radius of 15 cm is 3.5 μ Sv/h. Doubling the distance to the patient to 2 meters reduces the dose rate by a factor of 4 to 0.9 μ Sv/h. The same dose in a patient with an abdominal radius of 25 cm yields a dose rate at 1 meter of 2.6 μ Sv/h. The generally accepted threshold for discharge of the treated patient from the hospital is 20 μ Sv/h.

In most countries, the exposure limit for hospital staff is set the same as for the general public at 1 mSv/year.

When taking the 3.5 μ Sv/h dose rate as an average, this would allow hospital staff to work approx. 300 hours/year in close vicinity of patients treated with Theralugand-labelled radiopharmaceuticals without wearing radiation protection. Of course, the nuclear medicine staff is expected to wear standard radiation protection.

Based on the above calculations for the highest currently applied in therapies single-dose  177 Lu activity, the expected radiation exposure of medical personnel, patient's family members and general public is considered acceptable in line with ICRP recommendations (Lutetium ( 177 Lu) chloride Billev RMP, 2022). However, procedural guidelines setting standards for radiation safety of nuclear-medicine employees (Cappon et al., 2023) and for the management of radiotherapy patients (Nelson et al., 2019) should be followed to reduce the risks of excess and inadvertent exposure

## 2.6.8.2. Adverse events

The safety evaluation of  177 Lu-DOTATATE therapy for treatment of SSTR-positive NETs is illustrated best from the following two prospective clinical trials:

## NETTER-1

This trial was a large, representative open-label, randomised, comparator-controlled Phase 3 trial investigated safety of  177 Lu-DOTATATE plus long-acting octreotide compared to high dose long-acting octreotide in a total of 231 patients (114 female, 117 male) with advanced inoperable, well-differentiated SSTR-positive midgut NETs

<div style=\"page-break-after: always\"></div>

During the whole study, seven (6%) of 111 patients in the ¹⁷⁷Lu -DOTATATE group had a grade 3 or worse treatment-related SAE, whereas SAEs were not collected in the control group during long-term follow-up. The incidence of treatment-related SAEs was low during long-term followup (in three [3%] of 111 patients). Notably, no new treatment-related SAEs were reported after the safety analysis cut-off, which was approximately 46 months after study start. Two (2%) patients developed MDS. No cases of acute myeloi d leukaemia were reported in the trial population.

Table 19: Overview of AEs: Study NETTER-1 (Pivotal trial for Lutathera EMEA/H/C/4123)

|                                     | 177 Lu-DOTATATE group        | Control group (n=110) p   | value   |
|-------------------------------------|------------------------------|---------------------------|---------|
| AE                                  | number of patients (percent) |                           |         |
| Any                                 | 106 (95)                     | 95 (86)                   | 0.02    |
| Related to treatment                | 95 (86)                      | 34 (31)                   | <0.001  |
| SAE                                 |                              |                           |         |
| Any                                 | 29 (26)                      | 26 (24)                   | 0.76    |
| Related to treatment                | 10 (9)                       | 1 (1)                     | 0.01    |
| Withdrawal from trial because of AE |                              |                           |         |
| Because of any AE                   | 7 (6)                        | 10 (9)                    | 0.46    |
| Because of AE related to treatment  | 5 (5)                        | 0                         | 0.06    |

Source: Strosberg et al. (2017) E=adverse event

Table 20 : Adverse events occurring in ≥10% of patients * : Study NETTER-1

| Event SOC PT               | 177 Lu-DOTATATE group (n=111)   | 177 Lu-DOTATATE group (n=111)   | Control group (n=110)        | Control group (n=110)        | p value #   |
|----------------------------|---------------------------------|---------------------------------|------------------------------|------------------------------|-------------|
|                            | Any Grade                       | Grade 3 or 4                    | Any Grade                    | Grade 3 or 4                 | Any Grade   |
|                            | number of patients (percent)    | number of patients (percent)    | number of patients (percent) | number of patients (percent) |             |
| Any AE                     | 105 (95)                        | 46 (41)                         | 92 (84)                      | 36 (33)                      | 0.01        |
| Gastrointestinal disorders |                                 |                                 |                              |                              |             |
| Nausea                     | 65 (59)                         | 4 (4)                           | 13 (12)                      | 2 (2)                        | <0.001      |
| Vomiting                   | 52 (47)                         | 8 (7)                           | 11 (10)                      | 1 (1)                        | <0.001      |
| Abdominal pain             | 29 (26)                         | 3 (3)                           | 29 (26)                      | 6 (5)                        | 1.00        |
| Diarrhoea                  | 32 (29)                         | 3 (3)                           | 21 (19)                      | 2 (2)                        | 0.11        |
| Distension                 | 14 (13)                         | 0                               | 15 (14)                      | 0                            | 0.84        |
| General disorders          |                                 |                                 |                              |                              |             |
| Fatigue                    | 44 (40)                         | 2 (2)                           | 28 (25)                      | 2 (2)                        | 0.03        |
| Oedema peripheral          | 16 (14)                         | 0                               | 8 (7)                        | 0                            | 0.13        |

<div style=\"page-break-after: always\"></div>

| Event SOC PT              | 177 Lu-DOTATATE group (n=111)   | 177 Lu-DOTATATE group (n=111)   | Control group (n=110)   | Control group (n=110)   | p value #   |
|---------------------------|---------------------------------|---------------------------------|-------------------------|-------------------------|-------------|
|                           | Any Grade                       | Grade 3 or 4                    | Any Grade               | Grade 3 or 4            | Any Grade   |
| Blood disorders           |                                 |                                 |                         |                         |             |
| Thrombocytopenia          | 28 (25)                         | 2 (2)                           | 1 (1)                   | 0                       | <0.001      |
| Anaemia                   | 16 (14)                         | 0                               | 6 (5)                   | 0                       | 0.04        |
| Lymphopenia               | 20 (18)                         | 10 (9)                          | 2 (2)                   | 0                       | <0.001      |
| Leukopenia                | 11 (10)                         | 1 (1)                           | 1 (1)                   | 0                       | 0.005       |
| Neutropenia               | 6 (5)                           | 1 (1)                           | 1 (1)                   | 0                       | 0.12        |
| Musculoskeletal disorders |                                 |                                 |                         |                         |             |
| Musculoskeletal pain      | 32 (29)                         | 2 (2)                           | 22 (20)                 | 1 (1)                   | 0.16        |
| Nutrition disorders       |                                 |                                 |                         |                         |             |
| Decreased appetite        | 20 (18)                         | 0                               | 9 (8)                   | 3 (3)                   | 0.04        |
| Nervous system disorders  |                                 |                                 |                         |                         |             |
| Headache                  | 18 (16)                         | 0                               | 5 (5)                   | 0                       | 0.007       |
| Dizziness                 | 12 (11)                         | 0                               | 6 (5)                   | 0                       | 0.22        |
| Vascular disorders        |                                 |                                 |                         |                         |             |
| Flushing                  | 14 (13)                         | 1 (1)                           | 10 (9)                  | 0                       | 0.52        |
| Skin disorders            |                                 |                                 |                         |                         |             |
| Alopecia                  | 12 (11)                         | 0                               | 2 (2)                   | 0                       | 0.01        |
| Respiratory disorders     |                                 |                                 |                         |                         |             |
| Cough                     | 12 (11)                         | 0                               | 6 (5)                   | 0                       | 0.22        |

Source: Strosberg et al. (2017)

* Shown are all AEs that were reported in at least 10% of the patients in the 177 Lu-DOTATATE group, with the exception of neutropenia, which was reported in less than 10% of the patients in the 177 Lu-DOTATATE group. The safety population included all patients who underwent randomisation and received at least one dose of trial treatment.

# P values were calculated with the use of Fisher's exact text.

AE=adverse event; PT=preferred term; SOC=system organ class

The most common AEs among patients in the  177 LuDOTATATE group were nausea (65 patients [59%]) and vomiting (52 patients [47%]). Other common AEs in the 177 Lu- DOTATATE group included fatigue or asthenia, abdominal pain, and diarrhoea; however, the majority of patients in whom these events were reported

<div style=\"page-break-after: always\"></div>

(≥97%) had events of grade 1 or 2 ( Table 20 ). The rates of grade 3 or 4 AEs were similar in the two groups; however, transient grade 3 or 4 neutropenia, thrombocytopenia, and lymphopenia were reported in 1%, 2%, and 9% of patients, respectively, in the 177 Lu-DOTATATE group versus in no patients in the control group.

## ILUMINET

A personalised, dosimetry-based  177 Lu-DOTATATE therapy was investigated by Sundlöv et al. (2022) in 96 patients (42 female, 54 male) with NETs.

Table 21: Adverse events: Study ILUMINET (n=96)

| Event                   | Early AEs n (%)              | Early AEs n (%)              | Late AEs n (%)               | Late AEs n (%)               |
|-------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|                         | Any Grade                    | Grade 3 or 4                 | Any Grade                    | Grade 3 or 4                 |
|                         | number of patients (percent) | number of patients (percent) | number of patients (percent) | number of patients (percent) |
| Clinical AE             |                              |                              |                              |                              |
| Fatigue                 | 60 (62)                      | 1 (1.0)                      | 9 (9.4)                      | -                            |
| Nausea / Vomiting       | 48 (50)                      | 1 (1.0)                      | -                            | -                            |
| Pain                    | 21 (22)                      | 1 (1.0)                      | -                            | -                            |
| Diarrhoea               | 19 (20)                      | -                            | -                            | -                            |
| Abdominal pain          | 18 (19)                      | 1 (1.0)                      | -                            | -                            |
| Flushing                | 7 (7.3)                      | -                            | -                            | -                            |
| Alopecia                | 6 (6.2)                      | -                            | -                            | -                            |
| Constipation            | 5 (5.2)                      | -                            | -                            | -                            |
| Depression              | 5 (5.2)                      | -                            | -                            | -                            |
| Infection               | 5 (5.2)                      | 1 (1.0)                      | -                            | -                            |
| Ileus                   | 2 (2.1)                      | 1 (1.0)                      | -                            | -                            |
| Thromboembolic disease  | 2 (2.1)                      | 2 (2.1)                      | 1 (1.0)                      | 1 (1.0)                      |
| Weight loss             | 2 (2.1)                      | 1 (1.0)                      | -                            | -                            |
| Biliary tract infection | 1 (1.0)                      | 1 (1.0)                      | -                            | -                            |
| Dehydration             | 1 (1.0)                      | 1 (1.0)                      | -                            | -                            |
| Laboratory AE           |                              |                              |                              |                              |
| Thrombocytopenia        | 58 (60)                      | 9 (9.4)                      | 10 (10)                      | -                            |
| Anaemia                 | 51 (53)                      | 1 (1.0)                      | 20 (21)                      | -                            |

<div style=\"page-break-after: always\"></div>

| Leukopenia            | 32 (33)   | 4 (4.2)   | 8 (8.3)   | 1 (1.0)   |
|-----------------------|-----------|-----------|-----------|-----------|
| Neutropenia           | 28 (29)   | 6 (6.2)   | 9 (9.4)   | 1 (1.0)   |
| Liver enzyme increase | 6 (6.2)   | 1 (1.0)   | -         | -         |

Source: Sundlov et al. (2022)

Note: Early AEs included events from the start of therapy to 3 months after completing step 1 and late AE events 12 months after the last treatment

AE=adverse event, n=number of patients.

Also in ILUMINET the overall toxicity was described as mild, with few grades 3-4 AEs detailed in the Table above (see Table 21 ).

The most common clinical events were grade 1-2 fatigue, nausea, pain, diarrhoea, abdominal pain, flushing, and alopecia. Haematological AEs were common, with grade 1-2 anaemia and thrombocytopenia occurring in &gt;50% of the patients. Grade 3 -4 laboratory findings were observed in 19% of patients, including haematological AEs and liver enzyme increase. Grade 34 toxicity occurred in &lt;10% of patients and was mostly haematological, with no grade 3-4 renal toxicity.

Regarding late AEs, the only clinical AE occurring in &gt;5% of the patients and persisting 12 months after treatment was grade 1 fatigue. There was one grade 3-4 clinical AE, a thromboembolic event. The only persisting laboratory findings were grade 1-2 haematological AEs, whereas all grade 3-4 AEs occurred in &lt;5% of the patients at 12 months.

During follow-up, two patients were diagnosed with acute myeloid leukaemia 2 and 4 years after the first cycle of  177 Lu-DOTATATE.

Plasma creatinine levels increased over time, leading to an increase in the frequency of grade 1 nephrotoxicity. Compared to baseline, less patients had a GFR &gt;60 after treatment. There was one case of grade 3 toxicity related to intercurrent nephrolithiasis. There was one case of grade 2 renal toxicity and no grade 3-4 events.

In addition, numerous further studies, predominantly retrospective analyses, investigated the safety and toxicity profile of  177 Lu-DOTATATE for treatment of SSTR-positive NETs and generally are in line with the findings of the prospective clinical trials mentioned above. Very informative is also the large retrospective analysis from Kwekkeboom et al (2008) also included in the Lutathera application for long term safety evaluation from 504 patients with NETs.

Acute AEs were nausea after 25% of administrations, vomiting after 10% of administration, and abdominal discomfort or pain after 10% of administrations. 2 patients were hospital ised within 2 days of the administration because of hormonereleased crisis. Temporary hair loss occurred in 62% of patients.

Haematotoxicity: Any haematologic toxicity grade 3 or 4 occurred in 9.5% of patients after at least one of several treatments. MDS occurred in 4 patients (0.8%) and was likely attributable to treatment in 3 of them.

Nephrotoxicity and hepatotoxicity: Two SAE cases of renal insufficiency were reported, both of which were probably unrelated to  177 Lu-DOTATATE treatment. 3 patients experienced serious liver toxicity: 2 cases were likely treatment-related and non-lethal; 1 lethal case was considered unlikely related to treatment.

<div style=\"page-break-after: always\"></div>

## 177 Lu-PSMA-617 in metastatic castration resistant prostate cancer

The safety risks of  177 Lu-PSMA-617 therapy for treatment of mCRPC is paradigmatic illustrated from the VISION trial, pivotal for the approval of Pluvicto in the EU (EMEA/H/C/005483). With respect to the safety outcome of other trials in this indication it appears that the findings are generally in line with the outcome in VISION.

PSMA is expressed in all types of prostate tissues. As it has been shown to be overexpressed in prostate tumours including its metastatic cells, as well as in mCRPC, it is an ideal target for prostate cancer diagnosis and therapy (Silver et al., 1997; Sweat et al., 1998). However, PSMA is not prostate specific and several other organs such as the kidneys, salivary glands, lacrimal glands, or small intestine also express PSMA (Sweat et al., 1998; O'Keefe et al., 2004). Therefore, proximal renal tubules and salivary glands, among others, are considered critical organs in patients receiving PSMA-RLT. Since  177 Lu-PSMA agents are predominantly excreted by kidneys, additional concerns relating to their potential nephrotoxicity and renal outcomes exist.

As already known from PRRT in NETs with  177 Lu-DOTATATE myelosuppression is the most important potential dose-limiting factor in RLT also relevant for  177 Lu-PSMA. Toxic effects to haematopoietic cells are mediated by both blood-driven recirculating ß -irradiation and scatter radiation from bone metastases.

The results of 3 prospective clinical trials and several other supportive safety results are available in this indication. Most studies have monitored AEs and any other safety-relevant parameters along with the efficacy of  177 Lu-PSMA as a radioligand for treatment of mCRPC.

## VISION (pivotal trial for approval of Pluvicto EMEA/H/C/005483)

This trial evaluated the clinical safety profile of  177 Lu-PSMA-617 in 831 patients with mCRPC who were previously treated with at least one androgen-receptor pathway inhibitor and one or two taxane regimens. This is the largest randomised study with  177 Lu-PSMA-617 that became pivotal for its approval in EU in Dec 2022.

Median duration of exposure to  177 Lu-PSMA-617 was 6.9 months (range, 0.3 to 10.2 months), with patients receiving a median of 5 cycles (range, 1 to 6) and with a median cumulative dose of 37.5 GBq (range, 7.0 to 48.3 GBq). The incidence of AEs of grade 3 or above was higher with  177 Lu-PSMA617 than without it (52.7% vs. 38.0%), but quality of life was not adversely affected (see Table 22 ).

Fatigue, dry mouth, and nausea were the most common AEs in the  177 Lu-PSMA-617 group, and these AEs were nearly all of grade 1 or 2. Grade 5 TEAEs occurred in 5/529 patients (0.9%) in the 177 Lu-PSMA-617 plus standard care arm (pancytopenia, n=2; bone marrow failure, n=1; subdural haematoma, n=1; intracranial haemorrhage, n=1) and none in the control arm.

The incidence of SAEs was 31.9% in the 177 Lu-PSMA617 treatment group and 25.4% in the standard care group, and drugrelated SAEs were reported by 8.1% in the 177 Lu-PSMA617 treatment group and 2.4% in the standard care group.

<div style=\"page-break-after: always\"></div>

Table 22:  Summary of Adverse Events: Study VISION

| Event                                                   | 177 Lu-PSMA-617 plus Standard Care (n=529)   | 177 Lu-PSMA-617 plus Standard Care (n=529)   | Standard Care Alone (n=205)   | Standard Care Alone (n=205)   |
|---------------------------------------------------------|----------------------------------------------|----------------------------------------------|-------------------------------|-------------------------------|
|                                                         | All Grades                                   | Grade ≥3                                     | All Grades                    | Grade ≥3                      |
|                                                         | number of patients (%)                       | number of patients (%)                       | number of patients (%)        | number of patients (%)        |
| Any AE                                                  | 519 (98.1)                                   | 279 (52.7)                                   | 170 (82.9)                    | 78 (38.0)                     |
| AE that occurred in >12% of patients                    |                                              |                                              |                               |                               |
| Fatigue                                                 | 228 (43.1)                                   | 31 (5.9)                                     | 47 (22.9)                     | 3 (1.5)                       |
| Dry mouth                                               | 205 (38.8)                                   | 0                                            | 1 (0.5)                       | 0                             |
| Nausea                                                  | 187 (35.3)                                   | 7 (1.3)                                      | 34 (16.6)                     | 1 (0.5)                       |
| Anaemia                                                 | 168 (31.8)                                   | 68 (12.9)                                    | 27 (13.2)                     | 10 (4.9)                      |
| Back pain                                               | 124 (23.4)                                   | 17 (3.2)                                     | 30 (14.6)                     | 7 (3.4)                       |
| Arthralgia                                              | 118 (22.3)                                   | 6 (1.1)                                      | 26 (12.7)                     | 1 (0.5)                       |
| Decreased appetite                                      | 112 (21.2)                                   | 10 (1.9)                                     | 30 (14.6)                     | 1 (0.5)                       |
| Constipation                                            | 107 (20.2)                                   | 6 (1.1)                                      | 23 (11.2)                     | 1 (0.5)                       |
| Diarrhoea                                               | 100 (18.9)                                   | 4 (0.8)                                      | 6 (2.9)                       | 1 (0.5)                       |
| Vomiting                                                | 100 (18.9)                                   | 5 (0.9)                                      | 13 (6.3)                      | 1 (0.5)                       |
| Thrombocytopenia                                        | 91 (17.2)                                    | 42 (7.9)                                     | 9 (4.4)                       | 2 (1.9)                       |
| Lymphopenia                                             | 75 (14.2)                                    | 41 (7.8)                                     | 8 (3.9)                       | 1 (0.5)                       |
| Leukopenia                                              | 66 (12.5)                                    | 13 (2.5)                                     | 4 (2.0)                       | 1 (0.5)                       |
| AE that led to reduction in 177 Lu - PSMA - 617 dose    | 30 (5.7)                                     | 10 (1.9)                                     | NA                            | NA                            |
| AE that led to interruption of 177 Lu - PSMA - 617 #    | 85 (16.1)                                    | 42 (7.9)                                     | NA                            | NA                            |
| AE that led to discontinuation of 177 Lu - PSMA - 617 # | 63 (11.9)                                    | 37 (7.0)                                     | NA                            | NA                            |
| AE that led to death *                                  | 19 (3.6)                                     | 19 (3.6)                                     | 6 (2.9)                       | 6 (2.9)                       |

Source: Sartor et al. (2021)

# Patients who had been randomly assigned to receive  177 Lu -PSMA -617 plus standard care and who did not receive 177Lu PSMA

--617 but did receive standard care were included in the control group (standard care alone) of the safety

<div style=\"page-break-after: always\"></div>

population; 3 patients had AEs during cycle 1 of  177 Lu -PSMA -617 therapy that led to the interruption (in 2 of 205 patients [1.0%]) or discontinuation (in 1 [0.5%]) of that therapy.

* Five AEs that led to death in the  177 Lu -PSMA -617 group were considered by the investigators to be related to the drug: pancytopenia (in 2 patients), bone marrow failure (in 1), subdural haematoma (in 1), and intracranial haemorrhage (in 1).

AE=adverse event

In a retrospective cohort analysis by Meyrick et al (2021), TEAEs during RLT with 177Lu-PSMA in patients with mCRPC included grade 3 or 4 haematological (12%), grade 1 or 2 renal (4.5%), and grade 3 or 4 clinical events (5.7%) (Meyrick et al., 2021). The following table shows treatment related adverse events with 177Lu-PSMA-617:

Table 23: Treatment-related adverse events in study by Meyrick et al. (2021 )

| Adverse event                         | Number of patients (%)*   |
|---------------------------------------|---------------------------|
| Haematological AE (grade 3 or 4 only) | 21 (12)                   |
| Thrombocytopenia                      | 6 (3.4)                   |
| Anaemia                               | 9 (5.1)                   |
| Lymphopenia                           | 10 (5.7)                  |
| Neutropenia                           | 1 (0.6)                   |
| Renal AE (grade 1 or 2 only)          | 8(4.5)                    |
| Acute kidney disease                  | 3 (1.7)                   |
| Chronic kidney disease                | 5 (2.8)                   |
| Clinical AE (grade 3 or 4 only)       | 9 (5.1)                   |

Source: Meyrick et al. (2021) [50]

*total number of patients, n=175

=adverse event

<div style=\"page-break-after: always\"></div>

## Table 24: Tabulated list of adverse reactions in Theralugand SmPC

Adverse reactions are divided into groups according to the MedDRA convention frequencies: Very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1   ,000 to &lt; 1/100), rare (≥ 1/10 ,000 to &lt; 1/1 ,000), very rare (&lt; 1/10 ,000), not known (cannot be estimated from the available data).

| MedDRA system organ class                                           | Frequency                                       | Frequency                                                                                     | Frequency                                 | Frequency             |
|---------------------------------------------------------------------|-------------------------------------------------|-----------------------------------------------------------------------------------------------|-------------------------------------------|-----------------------|
| MedDRA system organ class                                           | Very common                                     | Common                                                                                        | Uncommon                                  | Not known             |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                                                 | Refractory cytopenia with multilineage dysplasia (Myelodysplastic syndrome) (see section 4.4) | Acute myeloid leukaemia (see section 4.4) |                       |
| Blood and lymphatic system disorders                                | Anaemia Thrombocytopenia Leucopenia Lymphopenia | Neutropenia                                                                                   |                                           | Pancytopenia          |
| Endocrine disorders                                                 |                                                 |                                                                                               |                                           | Carcinoid crisis      |
| Metabolism and nutrition disorders                                  |                                                 |                                                                                               |                                           | Tumour lysis syndrome |
| Gastrointestinal disorders                                          | Nausea Vomiting                                 |                                                                                               |                                           | Dry mouth             |
| Skin and subcutaneous tissue disorders                              | Alopecia                                        |                                                                                               |                                           |                       |

Description of selected adverse reactions

Dry mouth

Transient dryness of the mouth has been reported among patients with metastatic castration resistant prostate cancer receiving PSMA-targeting lutetium ( 177 Lu)-labelled medicinal products.

Alopecia

Alopecia, described as mild and temporary, has been observed among patients receiving lutetium ( 177 Lu)based peptide receptor radionuclide therapy for neuroendocrine tumours.

<div style=\"page-break-after: always\"></div>

## 2.6.8.3. Serious adverse event/deaths/other significant events

No data were submitted by the applicant. Reference is made to the literature review below by indication.

NETS: From NETTER-1 it reported that sixtyseven patients (30.0%) from both arms experienced at least one SAE, 37 (33.0%) patients in the Lutathera arm, 30 (27.0%) patients in the Octreotide LAR arm. The number of patients with at least one TESAE was 35 (31.3%) patients in the Lutathera arm, 27 (24.3%) patients in the Octreotide LAR arm, differences between the treatment arms in the occurrence of TESAEs were not statistically significant (p&gt;0.05). The number of patients who experienced TESAEs considered by the Investigator to be related to study treatment was 13 (11.6%) patients in the Lutathera arm and 3 (2.7%) patient in the Octreotide LAR arm.

In the NETTER-1 study, one patient of the Lutathera arm died due to a non-treatment emergent AE. Sixteen other patients (7.2%) died due to TEAEs in the course of this study: 7 patients (6.3%) of the Lutathera and 9 patients (8.1%) of the Octreotide LAR arm . None of these fatal TEAEs was related to the study medication.

mCRPC: From Pluvicto in the VISION trial more patients in the 177Lu-PSMA-617+BSC/BSoC arm than in the BSC/BSoC only arm had SAEs (177-LuPSMA: 36.3% vs BSC/BSoC only: 27.8%). However, this could be expected in a trial using BSC/BSoC as comparator. The impact of radiation toxicity on safety becomes even more clearly in the frequency of drugrelated SAEs, which occurred threefold in 9.3% patients in the 177Lu -PSMA617+BSC/BSoC arm and 2.4% patients in the BSC/BSoC only arm.

The SOCs with TEAEs reported in at least ≥5% of the patients in either arm were ( 177 Lu-PSMA vs BSC/BSoC only) were infections and infestations (9.8% patients vs. 4.4% patients).

SAEs with fatal outcomes occurred only slightly more in the 177Lu-PSMA617+BSC/BSoC arm: 19 (3.6%) patients in the  177 Lu-PSMA-617+BSC/BSoC arm (including 1 disease progression and 1 COVID-19); and 6 (2.9%) patients in the BSC/BSoC only arm (including 1 disease progression). However, again the difference of treatment duration on randomised treatment between the arms need to be considered for interpretation, since it was significantly shorter in the BSC/BSoC only arm.

## 2.6.8.4. Laboratory findings

No data were submitted by the applicant. Reference is made to the literature review below by indication.

## NETS:

In the Lutathera arm, 49 patients (43.8%) had a lymphopenia (Grade 3 or 4) and 22 patients (19.7%) had an increased GGT (Grade 3 or 4) diagnosed post randomisation. In each of the following categories, between 4 and 7 patients (3.6% to 6.3%) showed post random isation Grade 3 or 4 hyperglycaemia, hyperuricemia, hypokalaemia, alkaline phosphatase increased, ASAT increased and ALAT increased. In the comparator arm, the following toxicities were notable: lymphopenia (5 (4.5%) patients), hyperuricemia (7 (6.3%) patients), GGT increased (18 (16.2%) patients), and alkaline phosphatase increased (10 (9%) patients).

Regarding the Grade 3 or 4 laboratory toxicities, no relevant differences were observed between the 2 arms, except for lymphopenia, leukopenia, neutropenia, and thrombocytopenia. A trend towards stabilisation then improvement in patients with longer follow-up is observed.

For the lymphocyte toxicity observed following PRRT it was demonstrated that only B lymphocytes are affected, with no opportunistic infection being reported after PRRT. Additionally, in the NETTER-1 study lymphopenia in the Lutathera arm was not associated with an increased rate of infections compared to the control arm. The majority of thrombocytopenia in the Lutathera arm was mild to moderate.

<div style=\"page-break-after: always\"></div>

## mCRPC (VISION):

With respect to haematology, the most frequent myelosuppression-related adverse events were anaemia, thrombocytopenia, lymphocytopenia, leukopenia, and neutropenia, which may be attributed to the effects of ionizing radiation on sensitive precursor cells in circulation or in the bone marrow close to metastatic bone lesions, but which may also be impacted by bone marrow impairment at baseline from prior therapy. These shifts were mainly by 1 or 2 grades up, with some shifts to grade 4. None of these haematological parameter shifts caused any unexpected safety concerns.

Clinical chemistry abnormalities observed during randomised treatment were generally similar in both treatment arms (≤10% differences) with few noteworthy exceptions of hyponatremia (38.2% patients vs. 24.9% patients); hypocalcaemia (43.1% patients vs. 31.7% patients); and AST increased (31.2% patients vs. 21.0% patients). In both treatment arms, grade 3 / 4 abnormalities were infrequent (&lt;3.0% patients). Some shifts to higher grades were observed during the randomised treatment period but there was no trend; and none of these shifts raised any safety concerns.

The liver function parameters were similar in both arms, and no notable high frequency was observed for any of the hepatic laboratory categories. The laboratory data did not raise any hepatic safety concerns. No patient in either arm had a constellation of values indicative of Hy's law during the randomised treatment. Also, during long term follow-up, liver function parameters were similar between both the groups of patients and similar to what was observed during the randomised treatment.

## 2.6.8.5. Safety in special populations

## Pregnant and lactating women

According to the SmPCs of authorised medicinal products containing lutetium-177, those medicinal products are contraindicated in established or suspected pregnancy or when pregnancy has not been excluded.

## Paediatric population

The proposed medicinal product is not intended for use in children and adolescents. As medicinal products containing  177 Lu are currently not authorised for use in the paediatric population, data on the safety of  177 Lulabelled tracers in this vulnerable population are scarce.

## Elderly

Due to the nature of the underlying diseases, a significant number of patients above the age of 65 years have been treated with  177 Lu-labelled tracers in the course of published clinical studies.

## Renal impairment

Radiolabelled peptides are mainly excreted by the kidney. Radiation nephropathy has been reported following peptide receptor radionuclide therapy for neuroendocrine tumours using radioisotopes.

## 2.6.8.6. Immunological events

No information provided.

## 2.6.8.7. Safety related to drug-drug interactions and other interactions

No data were submitted by the applicant.

177 Lu-PSMA-617 is metabolically stable both in vitro and in vivo , passively cleared through the kidneys and not a substrate of any of the investigated uptake or efflux transporters (i.e. MATE1, MATE2-K, OAT1, OAT3,

<div style=\"page-break-after: always\"></div>

OCT2, P-gp and BCRP) based on in vitro assessments. Therefore, it is unlikely to become subject to any metabolic- or transporter-mediated drug interactions.

## 2.6.8.8. Discontinuation due to adverse events

No data were submitted by the applicant.

Discontinuation from  177 Lu-RLT in both indication were mostly due to adverse events related to haematological toxicity, followed by renal toxicity and to a lesser extent GI toxicity (possibly as a result of the amino acids infused for renal protection).

## 2.6.8.9. Post marketing experience

Theralugand is not marketed as a drug in any country world-wide. Thus, no there is no postmarketing experience available. Information from medicinal products authorised in the EU containing the radionuclide lutetium-177 was presented. The applicant summarised the adverse events reported with these products. (See 2.6.8.2. )

## 2.6.9. Discussion on clinical safety

In accordance with the Annex 1 Part III of Directive 2001/83/EC, as amended, in the specific case of a radiopharmaceutical precursor intended solely for radiolabelling purposes, the primary objective shall be to present information which would address the possible consequences of poor radiolabelling efficiency or in vivo dissociation of the radiolabelled conjugate, i.e. questions related to the effects produced in the patient by free radionuclide. These aspects have been adequately addressed in the dosimetry of  177 Lu chloride section (above), focusing on the accumulation of free lutetium-177 ( 177 Lu 3+ ) in target organs. Furthermore, safety information from already authorised medicinal products containing the active substance lutetium ( 177 Lu) chloride was evaluated.

The safety data available for  177 LuCl3 have been thoroughly summarised and it is agreed that data allow an adequate characterisation of  177  LuCl3 as a precursor added to two clinical relevant carrier molecules in the currently already approved indications (NETs and mCRPC).

As a radiopharmaceutical precursor, Theralugand is not administered directly to the patient and therefore has no clinical safety concerns associated with its stand-alone use. In general, adverse reactions following the administration of a  177 Lu-labelled medicinal product prepared by radiolabelling with the proposed medicinal product will be mainly dependent on the specific medicinal product being used. Such information will be supplied in the SmPC/package leaflet of the medicinal product to be radiolabelled.

Safety concerns for the radiolabelling with  177 Lu might arise due to unstable labelling, resulting in the release of ionic  177 Lu into the body. However, complexing with the most commonly used for radiolabelling chelators like DOTA appears to be irreversible and the applicant thus stated that no free  177 Lu is administered or released from Theralugand. A summary of the available study data and the corresponding human estimates of the absorbed  177 Lu doses was submitted. Nevertheless, it is emphasised that in vitro and in vivo stability of the resulting complex needs to be thoroughly tested by the developer of each new  177 Lu-labelled compound; since this is, an essential prerequisite for its successful clinical application.

Since the safety can be assessed only for the final radiolabelled medicinal product and depends from the pharmacokinetics and the distribution of the carrier molecule radiolabelled with Theralugand, only non-clinical dosimetry data is available for  177 LuCl3 itself or other ionic forms of  177 Lu.

<div style=\"page-break-after: always\"></div>

Importantly, the safety of any  177 Lu-labeled carrier molecule will be needed to be addressed in a potential MA procedure of any of these newly developed radiopharmaceuticals. This aspect is generally beyond the scope of the application for authorisation of the radiopharmaceutical precursor  177 LuCl3.

In the very implausible case of a direct injection, the main safety concern is radiation toxicity to the bone marrow. Based on the animal dosimetry results for direct injection, bone marrow would be the most sensitive organ as it could receive a higher than acceptable radiation dose. This risk is adequately addressed in the Theralugand Risk Management Plan (see 2.7. Risk Management Plan) as well as in SmPC section 4.9. In case of an inadvertent administration of Theralugand, the radiotoxicity for the patient must be reduced by immediate (i.e., within 1 hour) administration of preparations containing chelators like Ca-DTPA or Ca-EDTA in order to increase the elimination of the radionuclide from the body. The following preparations must be available in medical institutions, which use Theralugand for labelling of carrier molecules for therapeutic purposes: Ca-DTPA (trisodium calcium diethylenetriaminepentaacetate) or Ca-EDTA (calcium disodium ethylenediaminetetraacetate). These chelating agents help with the elimination of lutetium ( 177 Lu) radiotoxicity by an exchange between the calcium ion in the complex and the lutetium ( 177 Lu) ion. Due to the capacity of the chelating ligands (DTPA, EDTA) of forming water soluble complexes, the complexes and bound lutetium ( 177 Lu) are rapidly eliminated by the kidneys. One gram of the chelating agents should be administered by slow intravenous injection over 3 - 4 minutes or by infusion (1 g in 100 - 250 mL of glucose, or sodium chloride 9 mg/mL (0.9%) solution for injection). The chelating efficacy is greatest immediately or within one hour of exposure when the radionuclide is circulating in or available to tissue fluids and plasma. However, a post-exposure interval &gt; 1 hour does not preclude the administration and effective action of chelator with reduced efficiency. Intravenous administration should not be protracted over more than 2 hours. In any case, the blood parameters of the patient have to be monitored and the appropriate actions immediately taken if there is evidence of radiotoxicity. The toxicity of free lutetium ( 177 Lu) due to in vivo release from the labelled biomolecule in the body during therapy could be reduced by postadministration of chelating agents.

Nevertheless, as with respect to efficacy, safety evaluation of Theralugand can be assessed from literature data and clinical trial for Somatostatin-Receptor positive Neuroendocrine tumours (SSTR-pos.NETs) NETs using  177 Lu-DOTATATE and treatment of metastatic castration resistant prostate cancer using  177 Lu-labelled PSMA derivatives ( 177 Lu-PSMA-617 and  177 Lu-PSMA-I&amp;T). In both indications specific products (Lutathera and Pluvicto) have been meanwhile approved in the EU.

It is noted that with both already approved therapies with  177 Lu-DOTATATE and  177 Lu-PSMA the safety profile is acceptable overall. The most common non-haematological AEs included nausea and vomiting, fatigue or asthenia, abdominal pain, and diarrhoea. The majority of these events are mild or moderate in intensity, and generally transient.

Haematological toxicity is a known risk of treatment with both  177 Lu-DOTATATE and  177 Lu- PSMA, with myelosuppression being a potential dose-limiting factor in RLT. Toxic effects to haematopoietic cells are mediated by both blood-driven recirculating ß-irradiation and scatter radiation from bone metastases. Indeed, haematological AEs were among the most common treatment-related side effects reported during therapy and predominantly presented as anaemia, leukopenia, and/or thrombocytopenia. However, haematolo gical toxicity was mostly mild or absent (in over 60% of patients), and often transient. Of note, most patients already had impaired haematological function prior to  177 Lu-based therapy due to preceding chemotherapy or other anticancer treatment. Women treated with  177 Lu-DOTATATE developed more frequently grade ≥2 thrombocytopenia or grade ≥ 3 anaemia compared with men. Myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) have been observed after treatment with lutetium ( 177 Lu)-based

<div style=\"page-break-after: always\"></div>

peptide receptor radionuclide therapy for neuroendocrine tumours (see section 4.8). This should be taken into account when considering the benefit/risk, especially in patients with possible risk factors like prior exposure to chemotherapeutic agents (such as alkylating agents).

Bone marrow toxicity, presenting in severe haematological effects (grade 3 or 4), occurred in 8 to 15% of patients treated with  177 Lu-DOTATATE or  177 Lu-PSMA. It was generally transient, and therapy was continued after nadir was passed. However, blood transfusion support might be necessary in some cases. In patients with mCRPC, myelosuppression was significantly more frequent in patients with pre-existing grade 2 cytopenia or high bone tumour burden. PHD after PRRT with  177 Lu-DOTATATE, defined as diagnosis of MDS, AML, MPN, MDS/MPN, or otherwise unexplained cytopenia (for &gt;6 months), was reported in up to 5% of the patients in the literature which is in line with the pivotal trials for Lutathera and Pluvicto.

Anaemia, thrombocytopenia, leucopenia, lymphopenia, and less commonly neutropenia may occur during radioligand therapy with lutetium ( 177 Lu). Most events are mild and transient, but in some cases, patients have required blood and platelet transfusions. In some patients more than one cell line may be affected and pancytopenia requiring treatment discontinuation has been described. A blood count should be taken at baseline and monitored regularly during treatment, in accordance with clinical guidance.

Grade 3/4 renal toxicity and hepatotoxicity were rarely reported in published literature. NET patients pretreated with chemotherapy had a higher risk to develop renal toxicity. Radiolabelled somatostatin analogues are excreted by the kidney. Radiation nephropathy has been reported following peptide receptor radionuclide therapy for neuroendocrine tumours using other radioisotopes. Renal function including glomerular filtration rate (GFR) should be assessed at baseline and during treatment and renal protection should be considered, in accordance with clinical guidance of the radiolabelled medicinal product.

Moreover, tumour lysis syndrome has been reported following lutetium ( 177 Lu) radioligand therapy. Patients with a history of renal insufficiency and high tumour burden may be at greater risk and should be treated with increased caution. Renal function as well as electrolyte balance should be assessed at baseline and during treatment.

Serious hepatotoxicity was reported in single patients only, many of whom had liver metastases. Liver function should be monitored regularly during treatment. Dose reduction may be necessary in affected patients.

There have been reports of carcinoid crisis and other syndromes associated with release of hormones from functional neuroendocrine tumours following lutetium ( 177 Lu)-based peptide receptor radionuclide therapy, which may be related to irradiation of tumour cells. Reported symptoms include flushing and diarrhoea associated with hypotension. Observation of patients by overnight hospitalisation should be considered in some cases (e.g., patients with poor pharmacologic control of symptoms). In case of hormonal crises, treatments may include: intravenous high dose somatostatin analogues, intravenous fluids, corticosteroids, and correction of electrolyte disturbances in patients with diarrhoea and/or vomiting.

The administration of radiopharmaceuticals creates risks for other persons from external radiation or contamination from spill of urine, vomiting, etc. Radiation protection precautions in accordance with national regulations must therefore be taken. This is also addressed in the product information. Point-source approximation shows that the average dose rate experienced 20 hours after administration of a 7.4 GBq dose of a lutetium ( 177 Lu)-labelled medicinal product (residual radioactivity 1.5 GBq) by a person at 1 meter distance from the patient's body centre with an abdominal radius of 15 cm is 3.5 µSv/h. Doubling the distance to the patient to 2 meters reduces the dose rate by a factor of 4 to 0.9 µSv/h. The same dose in a patient with an abdominal radius of 25 cm yields a dose rate at 1 meter of 2.6 µSv/h. The generally accepted

<div style=\"page-break-after: always\"></div>

threshold for discharge of the treated patient from the hospital is 20 µSv/h. In most countries, the exposure limit for hospital staff is set the same as for the general public at 1 mSv/year. When taking the 3.5 µSv/h dose rate as an average, this would allow hospital staff to work approx. 300 hours/year in close vicinity of patients treated with lutetium ( 177 Lu)-labelled medicinal products without wearing radiation protection. Of course, the nuclear medicine staff is expected to wear standard radiation protection. Any other person in close vicinity of the treated patient should be informed about possibilities to reduce his/her exposure due to radiation emitted from the patient.

Procedural guidelines for the management of radiotherapy, including regulations on patients' discharge, have been developed and should be strictly followed to avoid unnecessary radiation exposure. Information related to occupational hazards and radiation exposure to hospital staff and to the environment is properly addressed and captured in the product information for Theralugand (see section 12 of the SmPC). Before use, packaging and radioactivity should be checked. Activity may be measured using an ionisation chamber. Lutetium ( 177 Lu) is a beta ( β-)/ gamma emitter. Activity measurements using an ionisation chamber are very sensitive to geometric factors and therefore should be performed only under geometric conditions which have been appropriately validated. Usual precautions regarding sterility and radioactivity should be respected. Withdrawals should be performed under aseptic conditions. The vials must not be opened before disinfecting the stopper, the radiopharmaceutical precursor solution should be withdrawn via the stopper using a single dose syringe fitted with suitable protective shielding and a disposable sterile needle or using an authorised automated application system. If the integrity of the vial is compromised, the radiopharmaceutical precursor solution should not be used. The complexing agent and other reagents should be added to the vial with lutetium ( 177 Lu) chloride.  Free lutetium ( 177 Lu) is taken up and accumulates in the bones. This could potentially result in osteosarcomas. It is recommended to add a chelating agent such as DTPA prior to intravenous administration of lutetium ( 177 Lu)-labelled radiopharmaceuticals in order to form a complex with free lutetium ( 177 Lu), if such is present, leading to its rapid renal clearance. Adequate quality control of the radiochemical purity of ready to use radiopharmaceuticals gained after radiolabelling with Theralugand should be assured. Limits for radiochemical impurities should be set recognising the radiotoxicological potential of lutetium ( 177 Lu). Free non-bound lutetium ( 177 Lu) should be consequently minimised.

There have been reports of extravasation of lutetium ( 177 Lu)-labelled ligands in the post-marketing setting. In case of extravasation, infusion of the medicinal product should be immediately ceased, and the nuclear medicine physician and the radiopharmacist should be promptly informed. Management should be in accordance with local protocols.

With respect to special population it is considered that the applicant has used dose calculations through realistic anthropomorphic phantoms from software's for internal dosimetry (e.g. IDAC-Dose 2.1) and this is agreed. Also, it is agreed dosimetry extrapolation to paediatric population despite of there are currently no 177 Lu-labelled radiopharmaceuticals authorised for use in these populations. It is noted that IDAC-Dose 2.1 version 1.01 software is only for adults calculations and OLINDA/EXM version 1.0 has been used for the remaining populations (paediatric population).

Dosimetry is presented for both sex (male and female) and for paediatric population in two tables (see 2.6.2.2. mCRPC). In both tables, derived Effective dose according ICRP 60 is shown for each age population and sex-averaged dose derived according to ICRP Publication 103 is presented for the whole age population. This approach is considered adequate.

<div style=\"page-break-after: always\"></div>

## 2.6.10. Conclusions on clinical safety

For the purpose of an application for a radiopharmaceutical for radiolabelling, the safety of Theralugand has been adequately characterised and adequate measures have been set up to manage the risks associated with Theralugand.

## 2.7. Risk Management Plan

## 2.7.1. Safety concerns

Table 25: Summary of safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                        |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | • Radiation effects on persons who are unaware of the exposure when in close vicinity of the patient • Decreased blood cell count (anaemia, leukopenia, thrombocytopenia, neutropenia, lymphopenia, pancytopenia) • Myelodysplastic syndrome (MDS)/ Acute myeloid leukaemia (AML) |
| Important potential risks    | • Osteosarcoma • Radiation-induced nephropathy • Radiation-induced hepatotoxicity                                                                                                                                                                                                 |
| Missing information          | • None                                                                                                                                                                                                                                                                            |

## 2.7.2. Pharmacovigilance plan

No additional pharmacovigilance activities. Routine pharmacovigilance activities including adverse reactions reporting and signal detection are considered sufficient.

<div style=\"page-break-after: always\"></div>

## 2.7.3. Risk minimisation measures

Table 26: Part V.3 Summary table of pharmacovigilance activities and risk minimisation activities by safety concern

| Safety concern                                                                                             | Risk minimisation measures                                                                                                                                                                   | Pharmacovigilance activities                                                                                                                     |
|------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risk:                                                                                 | Important Identified Risk:                                                                                                                                                                   | Important Identified Risk:                                                                                                                       |
| Radiation effects on persons who are unaware of the exposure when in close vicinity of the patient         | Routine risk minimisation measures: SmPC sections 2, 4.1, 4.2, 4.4, 4.9, 6.4, 6.6, and 12 Restricted user group Legal status Radiation labelling Additional risk minimisation measures: None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None |
| Decreased blood cell count (anaemia, leukopenia, thrombocytopenia, neutropenia, lymphopenia, pancytopenia) | Routine risk minimisation measures: SmPC sections 4.4 and 4.8 Restricted user group Legal status Radiation labelling Additional risk minimisation measures: None                             | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None |
| Myelodysplastic syndrome (MDS)/ Acute myeloid leukaemia (AML)                                              | Routine risk minimisation measures : Restricted user group SmPC sections 4.4 and 4.8 Legal status Radiation labelling Additional risk minimisation measures:                                 | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities:      |

<div style=\"page-break-after: always\"></div>

| Safety concern                   | Risk minimisation measures                                                                                                                                                                             | Pharmacovigilance activities                                                                                                                      |
|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|
|                                  | None                                                                                                                                                                                                   | None                                                                                                                                              |
| Important Potential Risks:       | Important Potential Risks:                                                                                                                                                                             | Important Potential Risks:                                                                                                                        |
| Osteosarcoma                     | Routine risk minimisation measures: SmPC section 4.1, 4.2, 4.4, 4.9, 5.3, 6.6, 11, 12 Product label Restricted user group Legal status Radiation labelling Additional risk minimisation measures: None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None  |
| Radiation-induced nephropathy    | Routine risk minimisation measures: SmPC section 4.4 Restricted user group Legal status Radiation labelling Additional risk minimisation measures: None                                                | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection : None Additional pharmacovigilance activities: None |
| Radiation-induced hepatotoxicity | Routine risk minimisation measures: SmPC section 4.4 Restricted user group Legal status Radiation labelling Additional risk minimisation measures: None                                                | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection : None Additional pharmacovigilance activities: None |

<div style=\"page-break-after: always\"></div>

## 2.7.4. Conclusion

The CHMP considers that the risk management plan version 3.0 is acceptable.

## 2.8. Pharmacovigilance

## 2.8.1. Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## 2.8.2. Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.9. Product information

## 2.9.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the applicant and has been found acceptable for the following reasons:

No full user consultation with target patient groups on the package leaflet has been performed on the basis of a bridging report making reference to EndolucinBeta. The bridging report submitted by the applicant has been found acceptable.

## 2.9.2. Labelling exemptions

A request to omit certain particulars from the labelling as per Art.63.3 of Directive 2001/83/EC have been submitted by the applicant and has been found acceptable only partly by the QRD Group for the following reasons:

1. Omission of the 'name of the manufacturer' and 'expiry date' on the small immediate packaging units Acceptable
2. Usage of the smaller font size for the small immediate label and on the label of the acrylic insert of the lead container (outer packaging) Acceptable
3. Omission of the sentence ' 1 mL of solution contains 40 GBq of lutetium (177Lu) chloride at activity reference time (ART) ' on the lead container and metallic can label (outer packaging) Not acceptable. This information is considered radiologically safe for healthcare professionals due to the protection offered by shielding.
4. Omission of the sentence ' Keep out of sight and reach of children ' on the lead container and metallic can label (outer packaging) Acceptable

The particulars to be omitted as per the QRD Group decision described above will however be included in the Annexes published with the EPAR on EMA website, and translated in all languages but will appear in greyshaded to show that they will not be included on the printed materials.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The medicinal product Theralugand (lutetium ( 177 Lu) chloride) is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium ( 177 Lu) chloride.

## 3.1.2. Available therapies and unmet medical need

Theralugand was developed as a radiopharmaceutical precursor developed to be clinically used for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with 177 LuCl3. The most common, best described and already established in the routine clinical practice carrier molecules available for radiolabelling with  177 Lu are DOTA-coupled octreotate (DOTATATE) and PSMA, indicated for treatment of SSTR-positive NETs or mCRPC, respectively.

There are other available therapies based on Lutetium-177, but due to its radioactive characteristics (decay), granting a new marketing authorisation would improve the availability of these therapies.

## 3.1.3. Main clinical studies

In line with the Annex 1 Part III of Directive 2001/83/EC, as amended, on radiopharmaceutical precursors, relevant information on the clinical utility of the radiopharmaceutical precursor Lutetium ( 177 Lu) chloride when is attached to appropriate carrier molecules has been provided. Two compound types most commonly used with  177 Lu (DOTA-coupled octreotate, DOTATATE, and PSMA) were chosen to demonstrate the clinical utility of  177 Lu and to serve as basis for the benefit-risk assessment of  177 Lu-based therapies. In both indications the applicant has thoroughly reported the available information on efficacy and safety based on the available literature.

Appropriate bibliographic data from the literature were presented to support efficacy and safety of  177 Lu products in already approved RLT indications (SSR-pos-NETs and mCRPC) and illustrate the clinical use of 177 Lu-radiolabelled compounds in general.

## 3.2. Favourable effects

A review of the literature has been submitted in order to document the clinical utility of  177 Lu, in particular in the treatment of neuroendocrine tumours (NETS) and castration resistant metastatic prostate cancer (mCRPC). Both therapeutic options are meanwhile well established in clinical practice. Additional clinical data have been presented in indication specific  177 Lu-products radiolabelled with specific carrier molecules (octreotide and PSMA) showing a positive benefit-risk balance in controlled Phase III trial see Lutathera (EMEA/H/C/004123) EPAR for NET-tumours and Pluvicto EPAR for mCRPC (EMEA/H/C/005483)).

## 3.3. Uncertainties and limitations about favourable effects

Not applicable

## 3.4. Unfavourable effects

Unfavourable effects will mainly depend on the intended administration of  177 Lu when it is added to a carrier molecule.

<div style=\"page-break-after: always\"></div>

Safety concerns for the radiolabelling with  177 Lu might arise due to unstable labelling or inadvertent direct injection of Theralugand, resulting in introduction of free  177 Lu into the body. Since complexing with the most commonly used chelators like DOTA is claimed highly efficient and irreversible and no free  177 Lu is thereby administered or released from the chelate complexes (Maecke et al., 2003). In very implausible case of a direct injection, the main safety concern is radiation toxicity to the bone marrow as shown in the animal dosimetry results for direct injection.

After therapy with  177 Lu-labelled peptides, haematological toxicity, myelodysplastic syndrome, renal toxicity and liver toxicity have been reported. Haematotoxicity and dry mouth have been reported with  177 Lu-labelled PSMA-ligands in radioligand therapy for metastatic castration-resistant prostate cancer.

Specific risk associated with the use of  177 Lu-labelled DOTATATE and PSMA compounds should be primarily addressed in the MAs of the corresponding medicinal products.

Decreased blood cell count (anaemia, leukopenia, thrombocytopenia, neutropenia, lymphopenia, pancytopenia) and myelodysplastic syndrome/acute myeloid leukaemia as well radiation effects on persons who are unaware of the exposure when in close vicinity of the patient are included in the RMP as important identified risks. In addition, osteosarcoma, radiation nephropathy and radiation-induced hepatotoxicity are considered as important potential risks in the RMP. Moreover, corresponding special warnings and precautions for use are included in the SmPC accordingly.

## 3.5. Uncertainties and limitations about unfavourable effects

Toxicity of free lutetium ( 177 Lu) due to in vivo release from the labelled biomolecule in the body during therapy could occur. It is unclear to what degree is in vivo release likely to occur or how would such in vivo release be measured in practice. However, this issue depends also on the carrier molecule added to  177 Lu and will have to be clarified in the case of a specific application for approval.

## 3.6. Effects table

Not applicable.

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Lutetium ( 177 Lu) chloride is a radiopharmaceutical precursor intended to be used for radiolabelling of suitable carrier molecules (peptides, antibodies) which have been specifically developed and authorised for radiolabelling with lutetium-177. Therefore, clinical utility must be demonstrated. As required, the applicant has reviewed the literature in order to document the clinical utility of lutetium-177.

The quantity of Theralugand required for radiolabelling and the quantity of  177 Lu-labelled medicinal product that is subsequently administered will depend on the medicinal product to be radiolabelled and its intended use.

177 Lu is broadly used as a therapeutic radionuclide for radiolabelling of specific carrier molecules which are developed for targeted radiotherapies (currently authorised or experimental) of various oncologic diseases, such as NETs and prostate cancer.

The two most important, best described in the published literature and most common therapeutic indications approved in the EU for  177 Lu are currently the treatment of gastroenteropancreatic NETs (GEP-NETs) and the treatment of mCRPC (as Lutathera and Pluvicto, respectively).

<div style=\"page-break-after: always\"></div>

Unfavourable effects are mainly related to the radioactivity of  177 Lu. Adverse reactions following the administration of a  177 Lu-labelled medicinal product prepared by radiolabelling with the proposed medicinal product will be mainly dependent on the specific medicinal product being used. Therapy with these medicinal products is well tolerated and toxicity is manageable if protective recommendations and dose limits are followed, which have been adequately reflected in the product information.

## 3.7.2. Balance of benefits and risks

Theralugand is a radiopharmaceutical precursor and is not intended to be administered on its own to patients. As a result, the benefits and risks of the intended administration of  177 Lu will be assessed independently when it is added to a carrier molecule. For the purpose of an application for a radiopharmaceutical for radiolabelling, the clinical utility and the safety of Theralugand has been adequately addressed. Since the precursor  177 Lu products are a prerequisite for this type of RLT, a positive risk benefit balance can be confirmed from a non-clinical and clinical perspective.

## 3.7.3. Additional considerations on the benefit-risk balance

Not applicable.

## 3.8. Conclusions

The overall benefit/risk balance of Theralugand is positive.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Theralugand is favourable in the following indication(s):

Theralugand is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177Lu) chloride.

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

## Other conditions and requirements of the marketing authorisation

## · Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## · Risk Management Plan (RMP)

<div style=\"page-break-after: always\"></div>

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.